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Abstract……………. 
 
One of the major problems related with implantable biomaterials is the limited 
bioactivity and suboptimal integration with the host tissue. The functionalization of 
biomaterial substrates to insert biological cues by the immobilization of biomolecules at their 
surface has been proposed as effective to overcome some of these limitations. Different 
immobilization strategies can be followed (such as adsorption or covalent immobilization) 
however, a critical aspect to have in consideration is to keep the bioactivity of molecule 
functionality. Therefore, the work developed in this thesis aims to activate and functionalize 
the surface of electrospun polycaprolactone (PCL) nanofiber meshes by the insertion of 
chemical groups (i.e. amine groups) to achieve a covalent immobilization of antibodies. The 
immobilization of the defined antibodies will allow for the selective binding of growth factors 
(GFs), either recombinant or derived from a biological fluid such as Platelet Lysates (PLs) that 
are known to have high concentrations of autologous GFs.  
We determined the maximum immobilization capacity of the defined antibodies (i.e. 
TGF-β1, bFGF and VEGF) in the mentioned nanofibrous surface. The GFs of interest were 
further incubated into the corresponding biofunctionalized substrate, assessing the maximum 
binding capacity as well as the selective binding of the GFs from a pool of different proteins 
present in human platelet lysate samples. The bioactivity of the bound VEGF was further 
assessed by seeding and culturing a specific endothelial cell line (HPMEC-ST1.6R) over the 
biofunctionalized substrate. The biological data demonstrates that the immobilization strategy 
does not compromise the availability of the antibody neither the functionality of the bounded-
GF. The combination of two antibodies (i.e. bFGF and VEGF) was tested in a mixed 
experiment or in separate regions of the same mesh in a side-by-side configuration. For the 
mix design, the biofunctionalized nanofibrous substrate was able to selectively bind two 
different GFs from the studied biological fluid. For the side-by-side a watertight chamber was 
developed to physically separate the substrate into two different areas, each one with a 
defined antibody just to validate the concept. 
Our results confirm the efficiency of the immobilization method as well as the bioactivity 
of the bound GFs, showing a promising potential for the immobilization of different antibodies 
and corresponding GFs depending on the intended application. This strategy will enable 
designing advanced autologous therapies since both GFs and cells could be from the same 
donor, allowing the implementation of very effective and personalized therapies. 
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Resumo 
 
Um dos grandes problemas relacionados com a implantação de biomateriais é a limitada 
bioatividade e integração com o tecido local. A funcionalização de substratos de forma a inserir 
sinais biológicos através da imobilização de biomoléculas na sua superfície pode ser uma 
tentativa para ultrapassar estas limitações. Diferentes técnicas de imobilização podem ser 
realizadas (por exemplo, absorção e imobilização covalente); contudo, um fator importante a ter 
em consideração é manter a bioatividade da molécula. Nesse sentido, o trabalho desenvolvido 
nesta tese tem como objetivo a ativação e funcionalização da superfície de nano fibras 
produzidas por electrospinning através da inserção de grupos amina de modo a conseguir uma 
imobilização covalente dos anticorpos. A imobilização de anticorpos específicos permitirá uma 
ligação seletiva de fatores de crescimento (FC), que podem ser recombinantes, ou retirados a 
partir de um fluído biológico, neste caso o Lisado de Plaquetas, que é conhecido por apresentar 
grandes concentrações de fatores de crescimento. 
Ao longo deste projeto, diferentes ensaios foram realizados para determinar a capacidade 
máxima de imobilização de anticorpos (TGF-β1, bFGF e VEGF) no substrato acima mencionado. 
Os fatores de crescimento referidos foram então incubados no substrato nanofibroso 
correspondente, determinando a máxima capacidade de ligação, assim como a ligação 
específica dos fatores de crescimento a partir das diferentes proteínas presentes no lisado de 
plaquetas. A bioatividade do VEGF previamente ligado ao anticorpo foi determinada através de 
uma linha celular endotelial (HPMEC-ST1.6R). Os dados biológicos confirmaram que a estratégia 
de imobilização adotada não afetou a disponibilidade e funcionalidade do fator de crescimento. A 
combinação de dois anticorpos (bFGF e VEGF) foi testada misturando-os numa só solução ou 
então imobilizando-os lado a lado em áreas específicas da malha. No primeiro caso, através da 
mistura e consequente imobilização dos dois anticorpos, foi possível ao substrato 
biofuncionalizado selecionar dois fatores de crescimento distintos do Lisado de Plaquetas. Para a 
imobilização dos fatores lado a lado foi desenvolvido um sistema capaz de separar o substrato 
em duas áreas distintas, assegurando que as duas soluções não se misturavam. 
Estes resultados confirmaram a eficiência do método de imobilização, assim como a 
bioatividade dos FC. Com esta estratégia será possível selecionar diferentes fatores de 
crescimento tendo em vista a aplicação pretendida, bem como a implementação de uma terapia 
autóloga possibilitando o desenvolvimento de tratamentos mais efetivos e personalizados.  
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Chapter 1  
Introduction 
 
Growth factors immobilization for tissue engineering and regenerative medicine 
therapies 
 
 
1.1 Abstract 
 
To achieve a more effective and faster regeneration of tissues and organs, the 
immobilization of bioactive molecules at the surface of biomaterial substrates has attracted 
tremendous interest as a promising Tissue Engineering and Regenerative Medicine approach. 
Growth factors as bioactive molecules play a pivotal role in wound healing cascade and have 
a significant role in a wide range of cellular events, such as proliferation, migration, cell 
signaling and differentiation. There are different immobilization strategies that can be 
followed to functionalize the biomaterial substrates with growth factors. However, a critical 
issue is the preservation of the bioactive molecule functionality after immobilization. Covalent 
immobilization is able to accomplish those requirements, leading to the development of 
devices with high functionality and to successfully achieve localized and sustained growth 
factor availability. Biological samples, like platelet rich plasma (PRP), have gained special 
interest mainly due to the easy assessability, variety and autologous source of growth factors 
envisioning personalized therapies. In this introduction we will discuss the various growth 
factors immobilization strategies available and its applications. 
 
 
 
Key Words: Growth Factors, Immobilization, Biomaterials, Platelet Rich Plasma, 
Regenerative Medicine, Tissue Engineering 
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1.2  Tissue Engineering and Regenerative Medicine 
Injuries and diseases can affect tissues and organs which may result in the partial or 
total loss of function. When no medical intervention is conducted, the physiological response 
of the body is restricted and is mostly confined to the auto-regenerative process. This might 
be an effective response to small injuries, but does not lead to the restoration of the normal 
structure and function of large defects 1–3. In the last decades, the conventional treatment 
modalities relies on the replacement of the affected organ or tissue by synthetic implantable 
devices that can restore  the tissues’ or organs’ function 1,4. Current clinical therapies for 
restoring tissue structure and function largely rely on the: transplantation of organs (such as 
kidney, liver, heart, lung, pancreas); on the use of tissue transplants (such as autografts, 
allografts or xenografts), on the administration of growth factors (GFs) and on the 
implantation of artificial devices (metal-alloys, ceramics or other prosthesis) 1,5. Regrettably, 
these strategies not always have the desired outcomes mostly caused by immune rejection, 
insufficient biocompatibility, the required mechanical and physical properties, complicated 
surgical procedures, chronic inflammation and lack of clinical predictability. With artificial 
implantable devices, the patient needs to face problems often related with the reliability and 
the fitting of the device into the defect site. 
Due to the increased incidence of injuries and diseases, and the medical need to 
create more effective therapies for improving the outcome of current types of tissue loss, the 
field of Tissue Engineering and Regenerative Medicine (TERM) has proposed alternative 
solutions and strategies that can overcome some of those limitations 3,6. The increasing 
knowledge on wound healing and tissue formation physiology, as well as the advances made 
in materials science and cell biology, is essential to the development of effective strategies 1,3. 
The TERM research aims at replicate these physiological processes, in order to develop more 
efficient hybrid systems for a complete restoration of damaged organ or tissue 1,7–9. 
Tissue Engineering (TE) aims to create, replace and facilitate the regeneration of 
damaged or diseased tissue with the combination of three different fundamental factors: 
biomaterials (scaffolds), cells and bioactive molecules (in most cases GFs) (Figure 1.1). The 
final purpose of TE is to create a tissue construct that upon transplantation will give raise to 
similar tissue found in the body. 
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  TE approaches that  may be followed are: (a) the delivery of tissue-inducing molecules 
that stimulate host cells to function normally; and (b) the development of a 3D matrix or 
scaffold biomaterial in which cells grow to create a living 3D tissue substitute 7–9. The former 
strategy is the most commonly followed in the field of TE, where living cells are seeded in a 
natural and/or synthetic substrate in order to create implantable devices able to restore the 
function of tissues. In this strategy, the required bioactive molecules (such as GFs, cytokines 
and proteins) are often supplied in the culture medium or may be released by  drug delivery 
system 7,9,10.  
 
1.2.2 Requirements of a biomaterial scaffold 
The scaffold plays a unique role in the TE strategies since it is designed to serve as a 
temporary support for the cell proliferation, migration and differentiation, in order to form a 
hybrid tissue construct in vitro 4. During the past two decades, many studies have been 
conducted in the development of biomaterials scaffold with potential applicability in clinical 
TE strategies. For that reason, scaffolds should have the following properties: (a) promote 
cell-biomaterial and cell-cell interactions, cell adhesion and ECM deposition 7,11,12; (b) facilitate 
a sufficient transport of gases, nutrients and other soluble factors, to allow cell survival, 
Figure 1.1 The three fundamental components of a Tissue Engineering strategy: a) biomaterial 
scaffold; b) relevant cell communities and c) bioactive molecules. 
 6 
 
proliferation and differentiation 7,13; (c) biodegradability in a rate compatible to the kinetics of 
tissue growth 14;  (d) act as delivery vehicles for biomolecules and bioactive factors 13; (e) 
support the stress developed at the implant site and retain mechanical strength after 
implantation, 15; (f) the porosity and the pore size should allow the cell ingrowth, an uniform 
cell distribution and migration, an improved ECM deposition and facilitate neovascularization 
of the construct 7,16,17; (g) provoke a minimal degree of inflammation or toxicity in vivo 18. 
 
1.2.2 Cell sources 
The cell is the basic structural and functional unit of a living organism. Multicellular 
organisms are made up of many different cell types with specialized functions 19. These 
specialized cells enable performing specific functions. Depending on the final application and 
the tissue to be repaired, different cell sources can be selected and expanded in vitro such as 
the hematopoietic, endothelial, chondrocytes, osteoblasts, epithelial cells 20.   
When cells are used for TE approaches, a biopsy of a donor tissue is dissociated into 
individual cells. Indeed cells source can be xenogenic (such as bovine or porcine), allogenic 
(donor from the same species but from a different individual) or autologous (from the patient 
itself). The preferred cell source to use in a TE strategy is the autologous cells, where a 
biopsy of a donor tissue is obtained, followed by the cells dissociation and expansion in vitro, 
and, finally, their implantation into the host 10. One of the limitations of applying cell-based 
regenerative medicine therapies to organ replacement is the difficulty of obtaining sufficient 
number of cells in relevant therapeutically quantity, as well as the protocols of in vitro cell 
manipulation are not completely elucidated 21.  
While several tissues remain important cell sources of therapeutic relevant differentiated 
cells, stem cells have emerged as a very strong alternative. Stem cells have the remarkable 
potential to differentiate into different cell types in the body. They serve as an endogenous 
repair system, able to participate in the permanent homeostasis and maintenance of the 
organs dying cells. Stem cells are distinguished from other cell types by two important 
characteristics: they are unspecialized cells capable of renewing themselves through cell 
division (the self-renewal capacity) and they can give rise to specialized cell types under 
certain physiologic or experimental conditions (the differentiation capacity) 22–24. Therefore, 
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when a stem cell divides, each new cell has the potential either to remain as a stem cell or to 
become another cell type with a more specialized and differentiated function. 
Stem cells can be characterized as totipotent (ability to differentiate into the cells of 
all the tissues of an entire organism) pluripotent (the potential to differentiate into most 
specialized cells in the body, but not all the tissues of an organism) and multipotent (the 
ability to form multiple cell types). 23 There are different types of stem cells:  the embryonic 
stem cells (ESCs) 25, responsible for embryonic and fetal development and growth; the adult 
stem cells (ASCs)26, responsible for the growth, tissue maintenance, regeneration and repair 
of diseased or damaged tissue.  
 
1.2.3 Bioactive molecules: growth factors  
Different signals from the extracellular microenvironment can play significant roles 
over the cellular performance, namely insoluble extracellular matrix (ECM) macromolecules, 
diffusible/soluble molecules, and cell–cell receptors (Figure 1.2 a). Although the growth 
factors (GFs) belong to the category of soluble molecules, they can also be present in the 
immobilized form within the ECM.  The diffusible/soluble molecules (including the GFs) can 
have different ways of action over cellular activity: autocrine (cell secretes molecules that 
binds to receptors on that same cell, leading to changes in that same cell), paracrine (cell 
produces a signal to induce changes in nearby cells) and/or endocrine (communicate a 
molecule over a long distance; the signals are released from a cell, migrate with the 
bloodstream and can travel around the entire body) (Figure 1.2 b). Growth factors bind to 
specific receptors on target cells and regulate the gene expression controlling functions such 
as cell growth, tissue morphogenesis, wound healing and regeneration 6,27.  
 
Figure 1.2 The extracellular microenvironment (a) and cell  signaling trough soluble factors. 
Adapted from 28 
a) b) 
 8 
 
The bioactive signals (like proteins, GFs, cytokines) involved in tissue repair or function 
restoration also can play a fundamental role in TERM strategies. A precise control over the 
levels and sequence of the signaling molecules within a specific location may positively  
regulate the regenerative processes 9,27. Proteins, especially GFs, have an important role in 
the regulation of a variety of cellular processes, namely in the growth, migration, 
differentiation and apoptosis of specific cells. Additionally, the activity of GFs is particularly 
connected  when an injury occurs, by coordinating the healing process, until the wound is 
completely repaired 6,27. Another important aspect related to the function of GFs is there 
crucial role in the exchange of information between different cell populations and their 
microenvironment (paracrine effect) 6,29,30. 
 
1.2.3.1 Growth factors and the healing cascade 
GFs are known to play a pivotal role in the complex cascade of the physiological repair 
mechanism by providing the needed signals to the cells and, thereby, leading to an 
accelerated functional restoration of damaged or defective tissue 31. Wound healing is a 
complex biological process that involves inflammation, mitosis, angiogenesis, synthesis of 
proteins and ECM remodeling 32. There are different GFs with different specific targets and 
functions that are involved in all the phases of the healing process:  Vascular Endothelial 
Growth Factor (VEGF), Basic Fibroblast Growth Factor (bFGF), Epidermal Growth Factor 
(EGF), Insulin Growth Factor (IGF), or Platelet derived growth factor (PDGF) 29,31,33. 
In a simple way, the healing cascade involves three different phases: inflammation, a 
trophic phase (including angiogenesis, proliferation and synthesis of ECM) and remodeling. 
When a tissue is damaged or injured, the healing cascade begins immediately when platelets 
come into contact with collagen. After platelet activation, clothing factors, cytokines and 
growth factors are released initiating the healing response 31,34.  
The inflammatory response is characterized by leucocyte extravasion and 
accumulation at the injury site, and monocyte/macrophage activation 35,36.  PDGF initiates the 
chemotaxis of neutrophiles, macrophages, smooth muscle cells and fibroblast. TGF-β is 
another important signal for the initiation of the healing cascade by attracting macrophages, 
stimulating them to produce additional cytokines like FGF that enhances collagen synthesis. 
TGF-β further enhances collagen expression leading to a strong response of the matrix 
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producing cells to ensure a rapid deposition of new connective tissue at the injury site and 
developing the fibrous cloth  37,38.  
The trophic phase includes the activation of endothelial cells to initiate the angiogenic 
process, which is the formation of new blood vessels able to promote blood flow, to support 
the high metabolic activity of the new tissue (avascular tissue are not comprise in this 
angiogenic phase)39. VEGF stimulates this process provinding a new blood supply to the 
injured site.  As the healing process progresses, several other important responses are 
activated. The cells  migrate into the injury site, using the fibrin matrix as a scaffold, then 
divide and differentiate, producing collagen, proteoglycans and other components of the 
natural ECM 31. Finally, during the remodeling stage, there is a decrease in cell density and, 
therefore, on the metabolic activity of the injured tissue. As stated above all these processes 
are mediated and activated by signaling molecules, like GFs, that limit the duration of each 
phase and promote the progression into the next stage 31,40,41. 
The basis of TERM research relies on the engineering of a microenvironment able to 
mimic the critical aspects of the natural healing process, namely the wound healing cascade, 
by providing suitable biochemical and physical factors.6 However, due the high complexity of 
this process these biological systems are not easy to recreate in vitro 6. 
Therefore it is absolutely necessary to provide the cells with a local biochemical and 
mechanical niche that can mimic the natural environment in which they can proliferate and 
differentiate efficiently, by creating an artificial ECM and by delivering GFs. In order to induce 
the regeneration and to accelerate the capability of tissue growth, it is fundamental to create 
an environment that can mimic the natural wound healing cascade. Due to all these aspects, 
the integration of GFs and the development of biomaterials that mimic the ECM 
microenvironment play an important role in the cellular regulation of adhesion, proliferation, 
differentiation and gene expression.  
 
1.2.3.2 Growth factors: properties and roles  
GFs have different mechanisms of action depending on the concentration, on the half-
life time, on the phenotype of the target cells as well as on their presentation (soluble or 
immobilized in the ECM) 6,30,42.  The local and systemic administration of GFs are therapeutic 
alternatives used in the treatment of chronic wounds (like ulcers, post-surgical wounds) as 
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well as the repair and regeneration of tissues in different fields like plastic surgery, 
orthopedics and cartilage lesions, muscle injuries and skin 29,30. The different GFs used in 
therapeutic applications are presented in Table 1. 
 To be effective as a therapeutic agent, a GF has to reach the target site without 
suffering biological degradation and, it has to remain at the target location sufficient time to 
exert its actions. GFs that are provided exogenously in solution at the site of the injury tend to 
be not effective because they tend to diffuse away from the wound site, being susceptible to 
enzymatic digestion or inactivation 6. In summary, various aspects have a significant effect on 
the therapeutic efficacy of GFs, including their short half-life in vivo, the side-effects caused by 
the administration of multiple or high doses of GFs to reach the desired effect at the target 
cells, and the possible denaturation of the GFs during manipulation and circulation. All these 
issues should be taken into account when designing a successful GF-based therapy 6,43,44. 
When designing an implantable system, some specific requirements related to the GFs 
should be of prior interest: the type of GF to be used and its final application; a feasible 
preparation method that does not affect the GF bioactivity; a robust system that can restrict 
the protein conformational mobility and protect the protein from physical and chemical 
degradation; a high loading efficiency; the ability of the system to retain the GFs at the site of 
action; a presentation of the GFs that mimics the temporal profile of the healing process in 
vivo 6,45,46. 
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Table 1 Most commonly used Growth Factors: biological role and targets 
GF ROLES TARGETS REFERENCES 
TGF-1  
Promotes the production of extracellular matrix; 
Modulates and enhances the proliferation of 
fibroblasts; 
Increases and stimulates synthesis of collagen 
type I; 
Enhances the proliferation of bone cells. 
Bone/ 
Cartilage 
47–50 
FGF 
Potent inductor of cell proliferation; 
Promotes angiogenesis and differentiation; 
Collagen production. 
Bone/ 
Cartilage/ 
Periodontal tissue 
51–53 
PDGF  
Stimulates fibroblast production, angiogenesis 
and macrophage activation; 
Collagen synthesis. 
Cartilage/ 
Bone/ 
Angiogenesis 
54,55 
EGF  
Triggers the expression of genes that leads to 
DNA synthesis and proliferation; 
Promotes mesenchymal and epithelial cell 
differentiation, angiogenesis and proliferation. 
Skin/ 
Cornea/ 
Nervous System 
56–58 
IGF 
Chemotactic for fibroblast and stimulates 
protein synthesis; 
Enhances bone formation by the proliferation 
and differentiation of osteoblasts. 
Bone/ 
Dermal wound healing/ 
Pancreatic stem cell 
differentiation 
59–63 
VEGF  
Promoter of angiogenesis and vasculogenesis; 
Proliferation of endothelial cells; 
Increases microvascular permeability. 
Vascularization/ 
Stem cell differentiation 
64–66 
 
 
1.3 Growth factors sources 
Peripheral blood is constituted by different cellular elements like red blood cells, 
white blood cells and platelets. These components are found in the peripheral circulating 
blood and are not retained and sequestered by the lymphatic system, spleen, and liver. 
Certain medical conditions in which the patients lose some of the blood components may 
require a blood transfusion. Nowadays, there is no need to make a transfusion of the whole 
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blood, being possible to select only the components of interest (like platelets, plasma, 
clothing factors) 67,68.  
In the past decades, platelet rich plasma (PRP) has been increasingly used in many 
medical fields, with particular interest in orthopedics and musculoskeletal disorders in 
athletes that need a fast recovery and early return to competition 31,69,70. PRP is described as 
“a fraction of autologous plasma containing an above baseline platelet concentration and 
growth factors which take part in the post-traumatic healing process”71. Therefore, to be 
defined as PRP, the platelet count should be at least 1 000 000 platelets/µl, whereas a 
platelet normal count ranges from 150 000 to 350 000 platelets/µl. Since platelets are a 
source of GFs, there is a growing interest in the use of PRP as a strategy to optimize the 
healing of the tissues 72.  
The impact of the discoveries regarding the potential of PRP healing has increased 
the optimism about autologous based regenerative medicine. PRP is also a cost-effective 
product, since it is taken from a simple blood samples and, therefore, it is easy to implement 
this cost-effective source in the current clinical practice. The Figure 1.3 depicts the 
simplicity of the PRP preparation procedure. Additionally, since PRP is a concentrated extract 
of lysed platelets, it is also a source of fundamental growth factors that are secreted by the 
platelets when a wound healing process is initiated. Because it is an autologous source of 
GFs, less regulatory concerns exist about its biosafety, since the immunogenic reaction and 
the possibility of disease transmission are eliminated. However, due to its complex 
composition of proteins, growth factors and cytokines, the mechanisms of action and dosage 
still  need to be elucidated41,73.  
   
13 
 
 
 
The possible use of PRP as an alternative biological source of bioactive agents has  
gained a special and exciting interest in TERM approaches 31,73. The use of PRP aims to take 
advantage of autologous source of bioactive molecules, such as GFs, proteins and cytokines, 
envisioning an autologous therapy where it is possible to use patient specific therapies. 
Recent reports  suggest that the use of PRP may be an approach to develop clinically 
relevant materials (GFs+scaffolds) able to deliver GFs and simultaneously to allow cell 
culture, and ultimately, integrate the in vitro generated construct into the native tissue 
environment 41,74–76. However, there are some controversial works  where it is reported that the 
use of PRP is not effective 70,77,78. Since the use of PRP is still in an early stage, new 
preparation methods and applications need to be explored to maximize its efficiency in TERM 
strategies. It is also necessary to determine the optimum concentration of the various GFs 
present in the PRP, which result in more effective PRP-based treatments.  
 
1.4 Immobilization methods and strategies 
The GFs released in physiological environments are susceptible to inactivation by 
degradation, prior to the possibility of reaching the desired target cells. Therefore, high 
quantities of soluble GFs well above the physiological values may be needed to have the 
required effects at the cellular level. However, the delivery of high quantities of GFs may lead 
Plasma
Red Blood
Cells
Red Blood cells
White cells
Platelets
Plasma
Platelet + 
White cells
Figure 1.3 Schematic representation of the PRP process. In this procedure about 30 to 60 ml of 
blood is taken from the donor and centrifuged during 15 minutes and 3200 rpm. With this 
centrifugation step it is possible to separate the different constituents of the human blood. PRP can 
be storage until further use and upon activation PRP facilitates the local release of different GFs for 
tissue engineering therapies. 
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to undesired cells and tissues side effects related with toxicity. Biomaterial-based systems 
can be designed to deliver soluble GFs locally, but sometimes they can be ineffective and 
costly 6,42,79. To overcome some of these drawbacks on the use of GFs as therapeutic agents, 
the biofunctionalization of substrate surfaces by the immobilization of GFs has special 
interest mainly due to the need to optimize the biological performance of implantable medical 
devices 80.  
An important requisite of protein immobilization is the biocompatibility and bioactivity 
of the substrate surface, because it should interact positively with the native structure of the 
proteins and biomolecules 81. The substrate chemistry, particularly the availability of reactive 
groups, is an important factor to consider when selecting an appropriate immobilization 
strategy. The location of such reactive groups, relatively to the receptor-binding area of the 
GF structure, and the dimensions of the substrate are other important aspects to have in 
consideration. Furthermore, the immobilization of GFs generally requires the use of aqueous-
based chemistry, as most of the GFs are either not soluble or may become denaturated in 
the presence of organic solvents 6,42,82–84.  
This section will mostly be focused on the immobilization strategies that involve the 
direct binding of the GF to the surface of the biomaterial substrate. Different immobilization 
methods can be implemented to achieve the biofunctionalization of substrates such as 
adsorption, physical entrapment and covalent-immobilization 42,82. However, each 
immobilization method results in advantages as well as in limitations. Covalent 
immobilization is the most reported method, which leads to a strong and stable binding of 
the bioactive molecule to the substrate. However, the presence of functional groups is 
required in both the substrate and the molecule to be immobilized. In most of the cases, a 
linker reagent is necessary. With this method it is also possible to overcome the common 
problems associated to the adsorption method, namely the deadsorption or the denaturation 
of the antibody 82,85.  
 
1.4.1 Non-covalent immobilization 
The immobilization of GFs can be divided in two different main categories: non-
covalent and covalent immobilization. Non-covalent immobilization includes physical 
entrapment, adsorption or ionic complexation 83. Physical entrapment is often associated with 
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GFs encapsulation/incorporation into micro-particles or reservoirs. Adsorption of GFs typically 
takes advantage of direct interactions, such as surface electric -charge or other secondary 
interactions between the GFs and the substrates surface, or of indirect interaction via 
intermediate proteins or other biological molecules 83,86,87. A third approach of non-covalent 
immobilization of GFs to a biomaterial is ion complexation. Proteins with different isoelectric 
points may be used for polyion complexation with charged macromolecules. These methods 
tend to have some problems associated such as the desadsorption and the irreversible ion 
complexation that can cause protein inactivation and denaturation 9,83. 
 
To improve the stability and persistence of the GFs immobilization, and consequent 
delivery to target cells and tissues, covalent immobilization of GFs to the substrate emerged 
as an alternative approach. Despite being a more complex process, immobilization strategies 
can prolong GFs availability than those obtained with weak physical immobilization. Also, the 
covalent immobilization allows a spatial control over the GF distribution and reduces the 
amount of GFs required, thereby potentially reducing the cost and increasing the efficacy of 
various bioactive materials or engineered tissues. Furthermore, the presentation of GF in an 
immobilized form also has physiological relevance, as both soluble and matrix-bound GFs 
perform distinct functions in the in vivo environment 6,42,88. 
 
1.4.2 Covalent immobilization strategies 
For the covalent immobilization of bioactive molecules, different chemical and reactive 
groups are needed in both the substrate and the GFs of interest. For different covalent 
immobilization methods, different groups are required. The most common reactive groups of 
GFs are the amines or the carboxyl groups 84. Whereas in the substrate surfaces, besides the 
amines and the carboxyl groups, also double bonds, C-H, N-N and acrylates are frequently 
required89. If the substrates do not have the required chemical groups, chemical treatments 
can be performed to activate their surface. 
Covalent immobilization often requires a linker to achieve a more stable and strong 
binding of the GF to the substrate. For example, 1-Ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) couples the carboxyl groups to the amine groups, resulting in a stable 
amide bond. In this reaction, EDC reacts with carboxyl groups to form an o-acylisourea 
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intermediate, which further reacts with the amine-containing molecule. However, this 
intermediate is highly unstable in aqueous solution and susceptible to hydrolysis, which 
results in re-formation of the carboxylic acid. Thus, sulfo-N-hydroxysuccinimide (sulfo-NHS) or 
N-hydroxysuccinimide (NHS) may also be added to create a more stable amine-reactive sulfo-
NHS or NHS ester intermediate, which increases the efficiency of the reaction. This coupling 
procedure is simple, inexpensive, effective and can be performed under mild conditions 42,90,91.  
Other methods of GFs immobilization involve the use of a photo-initiated reaction, 
which allows the binding of the GFs to a substrate 92,93. The first step of this method relies on 
the functionalization of the GF with a photo-reactive group and, afterwards, the binding of the 
modified GF to the substrate surface take place upon exposure to a defined radiation 
wavelength (usually, ultra-violet light) 94. One significant advantage of the photo-immobilization 
method is the simple development of patterned GFs, which can be easily performed through 
the use of photomasks or by the precise irradiation of specific areas with laser light sources, 
leading to a spatial defined distribution of the immobilized GFs. The creation of immobilized 
GF patterns enables greater control over cell function. Like the GFs immobilization by the use 
of EDC, photo-immobilization is relatively simple and effective but the use of photomasks 
frequently involves expensive technologies. The use of crosslinking reagents or the photo-
immobilization approaches also may have problems related with the GFs bioactivity, 
bioavailability and protein configuration. Specifically, the potential caused to the damage GFs  
by the ultra violet light is considered the most important drawback 42,82,94. 
Functionalization of polymers with acrylate groups is a common method for the 
activation of biomaterials that can be further cross-linked upon exposure to UV. Crosslinked 
networks of acrylated polymers are formed via chain-growth polymerization of the acrylates, 
and this process is initiated by reactive centers, such as radicals, which are generated upon 
photo-cleavage of the initiator molecules. These free radicals propagate through the 
unsaturated vinyl bonds on the acrylated polymers, resulting in covalently crosslinked high 
molecular weight polyacrylate kinetic chains. However, the bioactivity and orientation of the 
immobilized GFs can be compromised. Because this immobilization strategy depends upon 
acrylate reaction with another acrylate, the types of substrates that can be used are generally 
restricted to acrylated polymers, such as PEG-DA 42,84,85. 
By immobilizing GFs onto the surface of biomaterials, they are more protected against 
cellular inactivation and digestion. As a result, the immobilized GFs have more sustained and 
   
17 
 
longer activity when exposed to physiological environments. Growth factor immobilization 
may also overcome the diffusion limitations of soluble GFs. While the soluble delivery of GFs 
elicits responses in the surrounding environment, covalently immobilized GFs may have the 
additional advantage of inducing local effects within the scaffold where the cells are seeded, 
maximizing its effect. Maximum interaction with cells in the implant sites facilitates 
integration with the host tissues 6,27,88.  
 
1.5 Applications of immobilized growth factors 
The effect of soluble GFs over the behavior and signaling of different cell types has 
been widely described in the last years. However, in what concerns the influence of 
immobilized GFs, the available information is sparse and the outcomes much less reported. 
Soluble GFs are recognized by their corresponding cell-surface receptors and, thereafter, are 
internalized as a complex. In the case of immobilized GFs, cells are not able to internalize 
those receptor-GFs complexes, leading to a more sustained activation of the intracellular 
pathways. Consequently, with the immobilization of GFs it is possible to achieve enhanced 
and unique cellular responses that cannot be achieved with soluble GFs 27,95. Due to the 
improved stability and spatial control offered by the immobilization of GFs, this approach may 
provide beneficial contributions for different tissue repair strategies. The next sections will 
focus on the most promising results on the application of immobilized GFs at the surface of 
substrates. The effects of immobilized GFs have been studied in various areas including 
angiogenesis, bone repair and regeneration, dermal wound healing, cartilage repair, 
pancreas and liver, nerves and stem cell differentiation. 
 
1.5.1 Angiogenesis  
One of the major problems associated with tissue engineered therapies is the lack of 
a functional and integrated vascular system. The flow of nutrients and oxygen and the cell 
metabolites are essential to maintain the viability and functionality of tissues. Particularly, an 
inadequate vascular system leads to mal-function in mass transport and gases exchange 
which may cause unwanted cellular necrosis 96,97. 
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Endothelial cells are the responsible for the capillary vascular network formation 
(angiogenesis). Almost all tissues depend on a blood supply, and the blood supply depends 
on endothelial cells, which form the linings of the blood vessels. Endothelial cells have a 
remarkable capacity to adjust their number and arrangement to suit local requirements 98. 
The formation of new blood vessels can occur during different events, such as wound 
healing, organ regeneration, and in the formation of the placenta, as well as in several 
pathological processes (e.g. tumor growth, rheumatoid arthritis, diabetic retinopathy). A 
switch to the angiogenic phenotype depends on a local change in the balance between 
angiogenic stimulators and inhibitors. Furthermore, angiogenesis process is regulated by a 
complex control system, mediated by soluble molecules, such as VEGF 99. In the in vivo 
physiological environment, both matrix-bound and soluble forms of VEGF can be found. 
Soluble VEGF is believed to induce endothelial cell proliferation, whereas matrix-bound VEGF 
tends to promote the vascular sprouting and branching associated to neovasculature. 
Immobilized VEGF has been found to successfully stimulate the proliferation of endothelial 
cells 65,99. 
Due to the short half-life and the transient effect of soluble VEGF the development of 
strategies to achieve a more controlled delivery and release of this GF is of utmost 
importance. Accordingly, the immobilization of VEGF has become a promising strategy to 
overcome these problems, as a more suitable system to have control over the angiogenic 
process and endothelial cell function. With this strategy a microvasculature system would be 
incorporated in some engineered biomaterial substrates and scaffolds leading to more 
efficient tissue engineered solutions 42,100. Recent reports demonstrated that the covalent 
immobilization of VEGF on different substrates and scaffolds improved the endothelial cells 
tubulogenesis as well as stimulates their proliferation 101,102. The release of soluble VEGF 
sometimes results in vessels that are not completely functional. For that reason, VEGF was 
also co-immobilized with other GFs in other to achieve a more efficient and functional 
angiogenic process. Angiopoetin-1 (a GF related to the vessels stability and maturation) was 
co-immobilized with VEGF and the biological results demonstrated a significant improved 
tubulogenesis, as well as endothelial cell infiltration 103,104. Another example of  GF involved in 
the angiogenesis process, PDGF-ββ was also immobilized to improve the formation of a 
functional engineered microvasculature 105. Despite significant efforts and promising results in 
developing a functional vascularization system by the immobilization of more than one GF to 
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improve angiogenic and vessel stability, those strategies still need further demonstration of 
efficacy.  
 
1.5.2 Other relevant applications: dermal healing, cartilage, bone and stem cells 
differentiation 
  The use of GFs has been explored in different tissues, namely in the healing of chronic 
dermal wounds, overcoming the problems often associated with pain, long-term recovery, 
high cost and unsuccessful treatment outcome. With the GFs immobilization approach, a 
more controlled bioavailability of the GFs is possible, overcoming the problems of inadequate 
delivery of soluble GFs. Also of note is the prolonging bioactivity and half-life of the GFs. EGF 
immobilization was reported in most studies of dermal wound healing, since it stimulates the 
migration and proliferation of dermal cells (example: fibroblasts) that play an important role 
in wound closure. It was demonstrated that lower amounts of immobilized EGF are needed, 
when compared to the soluble EGF, to have a positive effect over the cellular response 42,106–108. 
  Embryonic and adult stem cells have the capacity for self-renewal and also have the 
ability to differentiate into different cell types. Stem cell differentiation can be achieved in vitro 
by the application of different molecules and signals. Recent studies evaluated the response 
of stem cells to immobilized GFs. A wide range of final applications was explored including 
the immobilization of GFs to promote neural differentiation (PDGF-AA and IFN-ϒ) and VEGF 
immobilized to differentiate the stem cells into vascular or hematopoietic cell types 109–112. 
Recent efforts have focused on helping the body to restore cartilage, through cell-
based and/or biomolecules therapies. A variety of synthetic- and natural-origin polymers were 
proposed for this purpose, each of it with their benefits and drawbacks. To date, an ideal 
biomaterial has yet to be created that can promote the functional repair or regenerate the 
damaged cartilage 113. However, the addition of signaling molecules such as the GFs seems to 
be a promising control to facilitate cartilage regeneration therapies. 
  TGF-beta was proposed to stimulate chondrogenesis through intracellular pathways 114. 
TGF-3 was immobilized into different scaffolds to solve and treat some cartilage injuries and 
lesions. Also TGF-1 was immobilized at the surface of different polymers. In both cases the 
expression of chondrogenic gene markers was significantly increased, as well as the 
production of glycosaminoglycans and collagen type II, indicating that neo-cartilage was 
generated.  
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The gold standard treatment of bone fractures and other orthopedic injuries causing 
loss of bone tissue rely on the use of autologous bone grafts. However, despite their 
biocompatibility and exceptional osteoconductive properties, autografts are associated with 
donor site morbidity. The most widely used ostegenic inducing molecules are the BMPs 
(namely the BMP-2 and the BMP-7, already approved by the FDA for human use) that induce 
new bone formation and regeneration at specific sites (used for example 
in orthopedic applications such as spinal fusions and oral surgery) 115–117. In these products, 
BMPs are delivered to the site of the fracture by being incorporated into a bone implant, and 
released gradually to promote bone formation. However, the delivery method of BMPs often 
shows a lack of local retention and the need of high amounts of proteins to achieve the 
desired biological effects. The immobilization of such GFs may have favorable outcomes in 
bone tissue engineering strategies, as well as on the osteointegration of orthopedic implants, 
with the use of significantly lower amounts of GF to achieve effective osteogenic outcomes 42. 
BMPs were immobilized in different substrates such as PLGA scaffolds 118, chitosan 
membranes 119  and PCL scaffolds 120 showing that the biological effect of immobilized BMP-2 
can significantly increase the expression of osteoblastic differentiation markers, when 
osteogenic precursor cells are cultured. When comparing the in vivo efficiency of the soluble 
BMP-2 and the immobilized form, the immobilized approach showed that both the  amount 
of bone and its maturity have increased 42,118–120.  
 
1.6 Final Remarks  
The implementation of chemical immobilization strategies allows the development of 
highly effective GF delivery systems, promoting the direct interactions between the 
immobilized GFs and the resident cells and avoiding the potential side effects caused by 
systemic administration. The biggest challenge of this strategy relies on finding the correct 
balance between the GFs and the physicochemical properties of the scaffold that can 
regulate cell behaviors in designing highly effective strategies. By combining biomaterial 
scaffolds with immobilized GFs at the surface were cells are seeded it will be possible to have 
a strongest interaction with the host tissues 
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Chapter 2 
Materials and Methods 
The aim of this chapter is to describe, in detail, the materials used and the 
experimental methods carried out to achieve the experimental results presented below. Also, 
this chapter will provide some insights on the methodological fundaments to properly justify 
the methods selected to answer specific research questions of this experimental work. 
 
2.1 Materials 
Polycaprolactone (PCL; Mw = 70 000 – 90 000 determined by GPC), Chloroform 
and N,N-Dimethylformamide (DMF) were purchased to Sigma Aldrich, kept at room 
temperature and use as received. PLC belongs to the aliphatic polyester family, being 
characterized by good mechanical/elastic properties, low toxicity, biocompatibility and long-
term biodegradability. Anti-human TGF-1 monoclonal antibody was purchased from 
PrepoTech Inc. (Rochy Hill, NJ; USA), reconstituted in sterile water and kept at -20ºC until 
further use. Recombinant bFGF oligoclonal antibody (clone 7HCLC), was purchased from Life 
Technologies (Carlsbad, CA; USA), reconstituted in a phosphate buffer solution (PBS) and 
kept at -20ºC until further use. VEGF (JH121) antibody was purchased from Santa Cruz 
Biotechnology Inc. (USA) and kept at 4ºC until further use. All these antibodies have specific 
reactivity to human samples, and the host of the VEGF and the TGF-β1 antibodies was 
mouse, and for the bFGF antibody the host was a rabbit. Regarding the secondary 
antibodies, both Alexa Fluor® 488 donkey anti-rabbit IgG (H+L), with green fluorescence, and 
Alexa Fluor® 594 goat anti-mouse IgG (H+L), with red fluorescence, were purchased from Life 
Technologies (Carlsbad, CA; USA) and kept at 4ºC until further use. Alexa Fluor® 488 was 
used to recognize the immobilized bFGF antibody, whereas the Alexa Fluor® 594 was used to 
recognize the immobilized TGF-1 and VEGF antibodies. 
Growth Factors (GFs), namely the recombinant human TGF-1 (a protein composed 
of two identical 112 amino acid polypeptide chains linked by a single disulfide bond) and 
basic-FGF (a protein consisting of 154 amino acid residues) were expressed in Escherichia 
coli, whereas the recombinant human VEGF121 (a disulfide-linked homodimeric protein 
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consisting of two 121 amino acid polypeptide chains) was expressed in CHO cells, all 
purchased from PrepoTech Inc. (Rochy Hill, NJ; USA), reconstituted in sterile water and kept 
at -20ºC until further use. 
 
2.2 Methods 
2.2.1 Scaffold Fabrication and (Bio)Functionalization 
2.2.1.1 The processing technique Electrospinning 
The PCL nanofiber meshes (NFMs) were produced by the electrospinning technique. 
This processing methodology is an efficient and versatile technique used to produce ultrafine 
fibers ranging from nano- to micro-scales The methodology and the phenomena behind this 
processing technique has been extensively described 1,2. The typical electrospinning setup 
consists in a spinneret coupled to a polymeric solution reservoir, a high voltage power source 
and a collector, as depicted in Figure 2.1. Electrospinning involves the application of a high 
voltage to the polymeric solution, resulting in the ejection of the solution through the needle. 
Basically, this electrostatic force opposes the surface tension of the solution causing the 
initiation of a jet. As this jet travels from the needle to the collector, the solvent partially 
evaporates and a fiber mesh is formed in a defined conductive collector 1,2. 
 
 
 
For the production of the PCL NFMs, a 5 mL plastic syringe (B-Braun) and a needle 
with 0.8 mm circular external diameter tip was used to electrospun the PCL solution. A 17% 
Figure 2.1 Electrospinning setup composed by an electric power supply, a syringe pump and 
collector. 
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(w/v) PCL solution was prepared with an organic solvent mixture composed of Chloroform 
and DMF, in a 7:3 ratio as described elsewhere 3. Briefly the PCL solution was left to mix in 
the stirrer overnight. The mesh was electrospun by applying a voltage of 13.6 kV, a needle 
tip-to-tip to ground collector distance of 18 cm and a flow rate of 1mL/h. After the complete 
processing of a 1mL of solution, the NFM was left to dry for 1 day, to make sure that all 
solvent residues had been evaporated. The processed NFM was further cut into smaller 
samples of 1cm x 1cm for further assays. 
The produced PCL NFMs are characterized by a high specific surface area that in 
combination with the microporous structure facilitates cell adhesion, proliferation, migration 
and differentiation. NFMs are typically distinguished to mimic the extracellular matrix of many 
tissues, by imitating its fibrils morphology and by the diameter of the fibers, providing an 
adequate 3D microenvironment for cell-cell and cell-biomaterial interactions. All these 
physical properties are of great importance when considering the TE strategies 4. PCL is a 
biodegradable polyester with hydrophobic properties. Recently PCL had gained particular 
interest in research due to its potential use as a biomaterial mainly related with its 
biocompatibility and low toxicity and it is already used in clinical for very applications 
including resorbable sutures. 
 
2.2.1.2 Surface Functionalization of Electrospun Nanofibers  
PCL does not have amine functional groups, thus its surface needs to be activated, 
for further insertion of amine group. The activation of the surface was obtained by an 
ultraviolet-ozone (UV-O) irradiation (UV-O Cleaner®, model ProCleaner 220 from Bioforce 
Nanoscience). The UV-O method is a photo-sensitized oxidation process in which the 
molecules are excited and/or dissociated by the absorption of short-wavelength UV radiation. 
The products of this excitation reaction with atomic oxygen form simpler volatile molecules 
which desorbs from the surface. When both UV wavelengths (184.9 nm and 253.7 nm) are 
presented, atomic oxygen (O) is continuously generated, as well as ozone is formed and 
destroyed, simultaneously.  
Both sides of the NFMs were exposed during 4 minutes to UV-O irradiation, as 
previously optimized 5 . After this surface activation, amine groups were inserted (-NH2) at the 
surface of the electrospun meshes. It is possible that the amine groups can be introduced 
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onto the PCL surface by a reaction with diamine (e.g. hexamethylenediamine (HMD)), 
providing that one amine group reacts with the -COOH- group of the PCL to form a covalent 
bound, while the other amine group is unreacted and freely. Therefore, PCL NFMs were 
immersed in a 1 M HMD (Sigma Aldrich) solution during 1h at 37ºC. The amount of –NH2 
(2.83 ± 0.11 nmol/cm2) was determined indirectly by quantifying the amount of free –SH 
groups according to Ellman’s reagent method 5. Both treatments decreased the 
hidrophobicity of the electrospun NFM, affecting also the nanofiber mesh structure by 
breaking some of top fibers of the mesh, as it is visible in Figure 2.2 b). The uniformity in 
fiber diameter seems also to be affected by the treatment. 
 
 
Figure 2.2 SEM analysis of an electrospun PCL NFM at 500X magnification: a) not subjected to 
any physicochemical treatment and b) after UV-ozone and aminolysis functionalization. 
          
2.2.2 Antibodies Immobilization Strategy 
The main concept of this work is the immobilization of specific GFs from a pool of 
different proteins and GFs. One possible route to immobilize the GF of interest involves the 
use of antibodies as an intermediate linker. Antibodies or immunoglobulins are Y-
shaped proteins produced by B-cells and used by the immune system to identify and 
neutralize foreign objects such as bacteria and viruses, by recognizing a unique part of the 
foreign target 6.  
Antibodies have two different regions: a variable region that is specific of each 
antibody and a non-variable region that is common for each type of antibody (Figure 2.3). 
The specific and variable region is also known as the antigen binding site where only a 
specific antigen (GFs in the present case) can be linked. 
50 μm 50 μm
a) b)
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 Typically, there is a carboxyl group (-COOH) in the antibodies structure at the end of 
their non-variable region. This group is used to react with the amine groups (-NH2) that were 
previously inserted at the surface of electrospun nanofibers, leading to the covalent 
immobilization of an antibody to the polymeric substrate. This covalent immobilization step 
often requires a linker to achieve a more stable and strong binding. In the present work, the 
EDC/NHS (1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride/ N-
hydroxysuccinimide) (Sigma Aldrich) combination was used as a linker since it is one of the 
most widely reported linkers that enhances the efficiency of the immobilization. 
 
 
 
The required steps to immobilize an antibody at the surface of electrospun 
nanofibers, for further binding of the corresponding GFs from the PL are shown in Figure 
2.4. After the surface functionalization of the nanofibers by UV-O and aminolysis each 
electrospun mesh was placed in a 24 well-plate and the primary antibody was mixed with 
EDC/NHS for 15 min at RT, to activate the antibody. This primary antibody solution was 
further added to each functionalized electrospun NFM. After overnight incubation, this 
solution was removed and the NFMs were washed with PBS. Then, a 3% BSA blocking step 
was performed for 30 minutes at RT. The BSA solution was removed and the secondary 
antibody was added to determine the degree of immobilization (indirect method was used by 
quantifying the fluorescence of unbound secondary antibody). The fluorescent-labeled 
Figure 2.3 The antibody structure, representing the variable and the non-variable region, as well 
as the carboxyl group at the end of the former region. 
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secondary antibody was incubated for 1h at RT, and the fluorescence of the remaining 
solution was read out in a MicroPlate Reader (Synergy HT, BioTek). The different specimens 
of each sample were washed and reserved in PBS at 4ºC and kept in the dark, until 
fluorescent microscopy observation. Parallel experiments were performed to assess the 
binding efficiency of recombinant proteins and PL-derived proteins to antibodies. All the 
previous described steps were conducted expect the secondary antibody step that was 
replaced by adding these solutions (recombinant protein and PL samples) and incubating 
them during 1h at RT. Samples of recombinant proteins and from PL were kept and frozen 
until ELISA quantification. 
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Figure 2.4 Antibody and antigen immobilization strategy, applied to the electrospun PCL NFMs, 
for further detection by the fluorescence reading method (sequence of steps required) 
2.2.2.1 EDC/NHS ratio and concentration optimization 
EDC couples carboxyl groups to primary amines. Although NHS (N-hydroxysuccinimide) 
is not required for carbodiimide reactions, its use greatly enhances the coupling efficiency, 
leading to a two-step reaction (Figure 2.5). With the combination of EDC/NHS, amine 
reactive NHS esters can be available to react with any carboxyl-containing molecule (-COOH) 
7.  
 
EDC/NHS was dissolved in 0.1 MES(2-N-morpholino) ethanesulfonic acid) buffer with 
0.9% (wt/wt) NaCl, following pH adjustment to pH=4.7. To optimize the reactive action of this 
linker, three different parameters were tested: the ratio between EDC and NHS, the 
concentration of the EDC and NHS, and their final concentration in the primary antibody 
solutions. For the testing of the first parameter, five different EDC/NHS ratios were tested, 
i.e. 1:4, 1:2, 1:1, 2:1 and 4:1. After selecting the best EDC/NHS ratio, the next step was to 
test their concentrations. In this assay, four different concentrations were studied: 10mM 
EDC + 40 mM NHS, 26 mM EDC + 104 mM NHS, 50 mM EDC + 100 mM NHS and 100 
mM EDC + 400 mM NHS. With the optimized reaction conditions in terms of EDC/NHS ratio 
and respective concentrations, the final concentration of the linker in the antibody solution 
was assessed to the 1%, 5% and 10% concentrations. The optimized conditions for those 
Figure 2.5 EDC reacts preferentially with the carboxyl groups forming O-acylisourea, an unstable 
reactive ester. In combination with NHS forms a semi-stable amine-reactive ester. This NHS ester can 
readily react with the available amine groups at the surface of electrospun nanofibers. 
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three parameters (1:4 ratio; 50 mM EDC + 200 mM NHS concentration and 1% 
concentration) were the ones used in all further experiments. 
2.2.2.2 Optimization of Single Antibody Immobilization and Determination of the 
Standard Curves  
Three different antibodies were immobilized (anti-TGF-1, anti-bFGF and anti-VEGF) 
at the surface of the activated and functionalized electrospun nanofiber meshes. A wide 
range of primary antibody concentrations (from 0 g/mL to 20 g/mL) was tested in order 
to find the maximum immobilization capacity of the system. The electrospun NFMs were 
placed in 24 well-plates and 200 µl of each primary antibody concentration was added to 
each well/meshes. After overnight incubation at 4 ºC, each mesh was washed twice with 
300 µl 0.1 M PBS (5 min each time) and a blockage of 3% BSA was performed for 30 
minutes at RT. The BSA solution was removed and the secondary antibody (1:200 in PBS) 
incubated for 1h at RT. A microplate reading (Synergy HT-BioTek) was performed to quantify 
the fluorescence of unbound secondary antibody solution (n=3 samples, read in triplicate). 
For the TGF-1 and VEGF antibodies, Alexa Fluor® 594 was used and the reading parameters 
were the following absorption at 590 nm and the emission at 617 nm. In the case of the anti-
bFGF, the selected secondary antibody was the Alexa Fluor® 488 and the reading parameters 
were 495 nm for the adsorption and 519 nm for the emission spectrum. Negative control 
samples were also prepared, where all antibody immobilization steps were performed with 
the exception of the primary antibody incubation, which was substituted by PBS. 
In further experiments, the following optimized primary antibody concentrations were 
use: 4 g/mL for anti-VEGF, 8 g/mL for bFGF and 12 g/mL for TGF-1. To define the 
standard curve of each primary antibody, five concentrations were used to define a linear 
regression with a R2  always above 0.98.  
 
2.2.2.3 Mixed immobilization of two antibodies (VEGF and bFGF) 
With the attempt to demonstrate the possibility to immobilize more than one antibody 
in the same polymeric substrate, VEGF and bFGF antibodies were selected. To achieve this 
purpose, both antibodies were mixed in the same PBS solution at the concentrations 
optimized before, for a final volume of 200 µl solution per mesh. The antibodies mixture was 
incubated overnight at 4ºC and then the samples were washed twice with 0.1 M PBS (5 
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minutes each) and a 3% BSA incubation step for 30 min at RT was performed to block all the 
non-specific sites. The BSA solution was removed and the secondary antibody Alexa Fluor® 
594 (for anti-VEGF) was incubated for 1h at RT. The exceeding secondary antibody solution 
was collect for further quantification (n=3 samples, read in triplicate), as previously 
described, and the sample washed twice. The same approach was carried out for the 
secondary antibody Alexa Fluor® 488 (for anti-bFGF). Both secondary antibodies were 
prepared in a 1:200 concentration, diluted in PBS. A negative control sample was performed, 
without the immobilization of the primary antibodies, although all the other steps were done 
to allow observing the samples under laser scanning confocal microscopy.  
 
2.2.2.4 Side-by-side immobilization of two antibodies  
 
The side-by-side immobilization aimed to immobilize distinct antibodies in different 
areas of the same polymeric substrate. To achieve that purpose, a compartmental watertight 
chamber (Figure 2.6) was developed capable of physically divide a single 1cmx2cm 
functionalized electrospun NFM into two distinct areas, without the mixture of different 
solutions and respective antibodies. A device made of acrylic was developed, with 4 cm of 
external diameter and an internal chamber where the membrane was inserted. A 
compartmental watertight ring made of expanded Polyvinl Chloride (PVC), with a separation 
bar that allows the physical division of the electrospun NFM into two areas, is placed on top 
of the functionalized electrospun NFM. The chamber is sealed with 4 screws so that the 
compartmental ring makes pressure over the NFM and does not allow the solutions to diffuse 
from one side to the other. Two different antibody solutions containing VEGF and bFGF, were 
prepared at the concentrations described above and dropped over each side of the 
functionalized electrospun NFM. All the antibody immobilization steps (washings, BSA 
blocking and secondary antibody incubation) were performed, as previously described for the 
single antibody immobilization. The quantification of unbound secondary antibody was also 
performed and the samples recovered to characterize the spatial distribution of the 
antibodies by laser scanning confocal microscope. 
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Figure 2.6 Schematic representation of the compartment watertight device, that allows the 
simultaneous immobilization of two different antibodies in two areas of a single mesh. 
 
2.2.2.5 Laser Scanning Confocal Microscopy 
Laser Scanning Confocal Microscopy was conducted in order to characterize the 
spatial distribution of the antibodies at the surface of the electrospun PCL NFMs. In this 
technique, the biological molecules are labeled with a fluorescence maker (in this case Alexa 
Fluor® 594 and 488) and detected visually by selecting an appropriate wavelength (excitation 
at 495 nm for Alexa® 488 and 590 nm for Alexa 594). Emission at 570 nm for the red 
channel and at 540 nm for the green channel). In confocal microscopy, a laser beam is split 
and refocused just on the plane of interest. This reduces one problem of normal fluorescence 
microscopy where the entire sample is illuminated and both in-focus and out-of-focus points 
contribute equally to the signal. The greatest advantage is the possibility of making three-
dimensional maps of the samples to within a depth of around 100-200 μm. This is 
particularly relevant to demonstrate immobilized antibodies in PCL NFMs. The antibodies 
were immobilized as previous described and single (TGF-1, bFGF and VEGF) and multiple 
(mixed or side-by-side designs) samples were placed in glass slides and analyzed by laser 
scanning confocal microscopy (FluoView 1000, Olympus, Germany) at a 10x magnification.  
 
2.2.3 Recombinant and PL-derived growth factor quantification 
2.2.3.1 Platelets Lysate: Preparation and Activation 
Platelet Rich Plasma (PRP) was provided by “Instituto Português do Sangue”, which 
certifies the biological product according to the Portuguese legislation. The number of 
platelets was counted and the sample volume is adjusted to 1 million platelets per L. At the 
C=H
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C=H
C=H
C=H
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3B´s cell culture lab, the collected PRP samples were subjected to a 3 repeating 
temperature-shock cycles (frozen with liquid nitrogen at −196°C and further heated at 37 
°C) and the remaining platelets were eliminated by centrifugation. A pool of Platelet Lysate 
(PL) was stored at -20ºC until further use. At the time of each experiment PL solution was 
thawed and filtered with a 0.22 µm filter. 
2.2.3.2 Fluorescence-Linked immunosorbent Assay (FLISA)  
After optimizing the maximum concentration of immobilized antibody, the loading 
capacity of the correspondent GF was tested. For that, both the corresponding recombinant 
proteins and the PL were tested for each biofunctionalized system. Basically, after all the 
antibodies immobilization steps previously described, 200 µl of the recombinant protein 
solutions at different concentrations (ranging from 0 µg/mL to the concentration of each 
primary antibody) were incubated for 1h at RT. The unbounded recombinant protein 
solutions were collected and stored at -20ºC until further analysis. Two PBS washing steps (5 
minutes each) were made and the biofunctionalized systems were incubated overnight at 4ºC 
with the corresponding primary antibody. After removal of the exceeding primary antibody 
solutions, the biofunctionalized systems were washed again with PBS, another BSA blocking 
step was performed and the correspondent secondary antibody was incubated for 1 hour at 
RT. The fluorescence of unbounded secondary solutions was read at the microplate reader, 
in order to quantify the secondary antibody that has not been immobilized. When PL was 
used as the source of GFs, the same procedure was followed, although the recombinant 
protein solution was substituted by 200 µl of PL solution.  
 
2.2.3.3 Enzyme-Linked Immunosorbent Assay (ELISA) 
A complementary analysis was performed to access the amount of unbounded GFs, 
after incubation with biofunctionalized systems comprising antibodies immobilization. The 
original recombinant protein and PL solutions, before their incubation with the functionalized 
systems, were also stored at -20ºC and used to quantify the initial amount of GFs. For the 
GFs quantification, human basic-FGF and VEGF development ELISA kits were purchased 
from PrepoTech (Rochy Hill, NJ; USA) and stored at -20ºC, whereas the human TGF-1 
ELISA kit was bought from Boster Biological Technology (Fremont, Ca; USA) and kept at 4ºC 
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until further use. bFGF and VEGF development ELISA kits were a two-days procedure. In the 
first part, the primary antibody was added to the 96 well-plate (Nunc-Immuno™ MicroWell™ 96 
well solid plates, Sigma Aldrich) and left over night in order to be immobilized at the wells 
bottom. All solutions were prepared according to the manufacturer protocol. Briefly, four 
washing steps were made and a 1% BSA blocking step for 1h was performed. Both standards 
(0-1 ng/mL for VEGF and 0-4 ng/mL for bFGF) and samples were added in triplicate (100 µl) 
and incubated for 2 hours at RT. Another washing step was made and the detection antibody 
was left to incubate also for 2 hours. The plate was aspirated and washed, an Avidin-
horseradish peroxidase (HRP) conjugate was added in a 1:2000 concentration and left to 
incubate for 30 minutes at RT. 100 µl of an 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic 
acid (ABTS) liquid substrate was added to each well, and the plate was read at 405 nm and 
650 nm. 
The TGF-1 ELISA is a ready-to-use kit, where the plate has been previously coated 
with the antibody. Briefly, 100 µl of the standards (ranging from 0 pg/ml to 1000 pg/ml) and 
samples were added to each well and incubated for 1 hour and 30 minutes at 37ºC. The 
content was discarded and 100 µl of biotinylated human TGF-1 antibody working solution 
was added to each well and incubated for 1h at 37ºC. The plate was washed 3 times with 
0.01 M PBS and 100 µl of the Avidin-Biotin-Peroxidase complex (ABC) working solution was 
added to each well and incubated for 30 minutes at 37ºC. The plate was then washed five 
times with PBS and 90 µl of TMB color developing agent was added to each well and 
incubated in the dark for 20-25 minutes. 100 µl of the TMB stop solution was added to each 
well and the color changed to yellow. The absorbance at 450 nm was read in the microplate 
reader (Synergy HT, Bio-TEK). 
 
2.2.4 Biological Part 
2.2.4.1 Cell culture and seeding 
 
  A human pulmonary microvascular endothelial cell line (HPMEC-ST1.6R) was used to 
validate the developed biofunctionalized nanofibrous substrate. This cell line is used to study 
in vitro angiogenic process 8. 
HPMEC-ST1.6R cells 8 were cultured with M199 medium (Sigma Aldrich) 
supplemented with 20% FBS (Alfagene), 2 mM Glutamax (Life Technologies), Pen/Strep (100 
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U/100 g/mL; Life Technologies), heparin (50 µg/mL; Sigma Aldrich), Endothelial cell growth 
supplement (ECGS - 25 µg/mL; Becton Dickinson) and incubated at 37ºC in a humidified 5% 
CO2 atmosphere. HPMEC-ST1.6R cells were used at passages 30-32. Medium was changed 
twice a week until cell reached 90% of confluence. Then cells were harvested and seeded 
onto the activated and functionalized electrospun NFMs. 
  The electrospun PCL NFMs were sterilized by ethylene oxide at Pronefro® Produtos 
Nefrológicos, S.A. (Porto, Portugal). For NFM_AB1, NFM_Ab2, NFM-VEGFRec and NFM+VEGFPL, 
VEGF antibody was immobilized overnight and, after the BSA blocking step, human recombinant 
protein, human recombinant protein (VEGF=4 µg/mL) and PL were incubated. Cell seeding 
was performed by dropping a 50 µl cell suspension containing 50 000 cells per substrate 
and left overnight. After cell attachment, culture medium was added to each type of cells and 
conditions. Untreated electrospun PCL NFMs and NFMs where nanofibers were subjected to 
surface activation, aminolysis and primary antibody immobilization were used as controls. 
After 1, 3 and 7 days of culture, samples were collected for cell viability assay, DNA and total 
protein quantification and VEGF quantification. 
 
2.2.4.2 Cell Viability 
The MTS assay is a colorimetric method commonly used for cytotoxicity assays or for 
determining the number of viable cells in proliferation. The MTS assay is based on 
bioreduction of a novel tetrazolium compound, 3-(4.5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfofenyl)-2H-tetrazolium [MTS], into a brown formazan product 
that is soluble in tissue culture medium. The quantity of formazan product, as measured by 
the amount of 490 nm absorbance, is directly proportional to the number of living cells in 
culture 9.  
 The metabolic activity of HPMEC-ST1.6R cells seeded on untreated electrospun PCL 
NFM, NFMs with primary antibody immobilization, and biofunctionalized nanofibrous 
substrates (recombinant and PL-derived) was determined by the MTS assay (CellTiter 96 ® 
AQueous One Solution, Promega). Basically, at days 1, 3 and 7, the culture medium was 
removed and the samples were rinsed with sterile PBS. A mixture of culture medium and 
MTS reagent (5:1 ratio) was added to each mesh, as well as to the negative control 
comprising no cells or samples. All conditions were performed in triplicate and left to 
incubate for 3h, at 37 ºC in a humidified 5% CO2 atmosphere. Thereafter, the absorbance of 
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the MTS reaction medium from each sample was read in triplicate at 490 nm in a microplate 
reader (Synergy HT, Bio-TEK). 
 
2.2.4.3 Cell Proliferation 
The accurate determination of DNA concentration is essential for many processes in 
molecular biology and physiology 10.  Cell proliferation was determined by using a fluorimetric 
dsDNA quantification kit (Quant-iT™, PicoGreen®, Molecular Probes, Invitrogen, USA). The 
samples were collected at days 1, 3 and 7, washed twice with sterile PBS and transferred 
into eppendorf tubes containing 1 mL of ultrapure water. These samples were frozen at -80 
°C until further analysis. Prior to DNA quantification, the various specimens for each sample 
were thawed and sonicated for 15 min. DNA standards were prepared at concentrations 
ranging from 0 to 2 g/mL. Per each well of an opaque 96-wells plate (Falcon) were added 
28.7 L of sample or standard (n=3), 71.3 L of PicoGreen solution and 100 L of TE 
buffer. The plate was incubated for 10 min in the dark and the fluorescence was measured 
in a microplate reader (Synergie HT, Bio-Tek; USA) by using an excitation wavelength of 480 
nm and an emission wavelength of 528 nm. The DNA concentration of each sample was 
calculated using a standard curve relating DNA concentration and fluorescence intensity. 
 
2.2.4.4 Total Protein synthesis 
  Samples were collected and prepared for assaying, as previously described in the Cell 
Proliferation. For the quantification of total protein synthesis, a Micro BCATM Protein Assay Kit 
(Pierce, Thermo Scientific) was used. The assay was made accordingly to the manufacturer 
instructions. Briefly, standards were prepared at various concentrations ranging from 0 
g/mL to 40 g/mL in ultra pure water. 150 L of both samples and standards were 
assayed in triplicate and 150 l of working reagent were further added to each 96-well plate. 
The plate was sealed and incubated for 2 hours at 37 ºC. The plate was left to cool down to 
RT and, thereafter, the absorbance at 562 nm was measured in a microplate reader 
(Synergy HT, Bio-Tek). 
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2.2.4.5 Statistical analysis 
Statistical analysis was performed using Graph Pad Prism Software. Differences 
between the different conditions of the cellular assays were analyzed using non-parametric 
test (Kruskal-Wallis test) and a p<0.05 was considered significant. Data were presented as 
mean ± standard deviations. 
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Chapter 3 
Biofunctional Nanofibrous Substrate Comprising Immobilized Antibodies and Selective Binding of 
Autologous Growth Factors  
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Biofunctional Nanofibrous substrate comprising immobilized antibodies and 
selective binding of autologous growth factors  
 
 
 
Abstract 
 
The immobilization of biomolecules at the surface of different biomedical devices has 
attracted enormous interest, in order to enhance their biological functionality at the cellular 
level. This work aims to develop a biofunctional polymeric substrate capable of selectively 
bind Growth factors (GFs) of interest from a pool of proteins present in a biological fluid: 
Platelet Lysate (PL). Different antibodies were previously immobilized at the substrate 
surfaces, taking advantage of the specific binding between an antibody and its correspondent 
antigen. To achieve that purpose, the surface of electrospun PCL nanofibers were activated 
and functionalized in order to insert chemical groups for the immobilization of antibodies. 
After determining the maximum immobilization capacity of each antibody: TGF-1 (12 
g/mL), bFGF (8 g/mL) and VEGF (4 g/mL) the next step was to bind the correspondent 
GF. Using recombinant proteins almost 100% of the initial concentration was immobilized, 
whereas for PL-derived GFs the efficiency was of 84 - 87% for TGF-1, 55 - 64% for bFGF and 
50 - 59% for VEGF. With this immobilization method we succeeded in developing a platform 
for the quantitative measurement of either natural or recombinant proteins in a wide and 
higher efficiency than the ones already available. Cellular assays confirmed that the biological 
activity of the bound VEGF (both recombinant and PL-derived). Multiple antibodies (i.e. bFGF 
and VEGF) were also immobilized over the same structure in a mixed or side-by-side fashion.  
Using both biological fluids and cells from autologous sources, it is possible using this 
platform to implement very effective and personalized therapies, tailored for the needs of 
specific patient conditions. 
 
Key Words: Growth Factors, Biological Fluids, Antibodies, Covalent immobilization, 
Electrospun Nanofibers 
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3.1 Introduction 
The biofunctionalization of surfaces gained special interest by the need to optimize the 
biological integration of implantable medical devices 1. Of particular interest is the 
immobilization of antibodies, due to the high specific interaction with their ligand molecules, 
making a more efficient and irreversible attachment of the target protein/ligand. Protein 
immobilization requires that the substrate should provide a biocompatible and bioactive 
environment, since it should interact positively with the native structure of the proteins and 
biomolecules 2. Antibodies were previously immobilized onto different substrates such as 
solid surfaces 3, microfluidic platforms 4, carboxyl surfaces 5, micro arrays 6, ultra-flat 
polystyrene surfaces 7 and gold particles 8. The ultimate goal of the antibodies’ immobilization 
at the substrate surface is to create specific sites for stimulating cell and proteins adhesion 9. 
Different immobilization methods and strategies can be implemented to achieve the 
biofunctionalization of substrates such as physical adsorption, covalent immobilization or 
antibody-binding proteins 10. Covalent immobilization is the most reported method, since it 
leads to a strong and stable attachment. In this method the presence of functional groups is 
required in both the substrate and the molecule to be immobilized. Due to the use of 
coupling agents, modifications of the antigen binding site can occur which may cause loss of 
functionality of the antibodies. Therefore, there is the need to confirm that the biological 
activity of the corresponding bound antigen was not compromised. With this immobilization 
method it is also possible to overcome the problems related to the adsorption method, where 
often occurs deadsorption and antibody denaturation 9,10.  
Electrospun nanofiber meshes (NFMs) are very interesting polymeric substrates due to 
their high specific surface area, their flexibility in surface functionality and their physical 
fibrous structure mimicking  the morphology of the native extracellular matrix of most tissues 
11,12. Other important properties of electrospun NFMs are their high levels of porosity and a 
pore size smaller than the dimensions of most cells. Those features are of high importance 
for various applications in Tissue Engineering and Regenerative Medicine, since electrospun 
NFMs will have selective permeability to soluble factors hindering the permeation of cultured 
cells 13. 
Proteins, especially growth factors (GFs), have an important role in the regulation of a 
variety of cellular processes, as well as on the coordination of the healing process of different 
tissues 14. GFs functions and purposes range from inducing vascularization and angiogenesis 
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to cell growth, proliferation and differentiation. Therefore, the local or systemic administration 
of GFs may be a valuable therapeutic approach in the successful treatment of different 
chronic wounds 15. Clinically, GF-based strategies are applied in plastic surgery, bone and 
cartilage lesions, muscle injuries, ulcers and skin regeneration 16. Particularly, biological fluids 
such as the Platelet Lysate (PL), that consist of  a cocktail of different GFs (e.g. bFGF, VEGF, 
TGF-, PDGF-BB, EGF, IGF-I) provide a complex mixture of chemical signals to the cells at 
the injury site, which is often associated with a non-specific action 17,18. 
The leading goal of the herein presented work is to develop a highly biofunctional 
nanofibrous substrate, taking advantage of the specific and efficient interactions between a 
specific antibody and its antigen. With this strategy it is possible to selectively immobilize 
from a pool of highly concentrated GFs present in the PLs, just the ones of interest for the 
envisioned application (i.e. bFGF, TGF-1 and VEGF). Furthermore, this biofunctionalization 
strategy also enables the simultaneous immobilization of multiple antibodies at a time, 
distributed in a mixed or in a side-by-side fashion over the same nanofibrous substrate 
enabling designing studies to elucidate the synergistic effect of the combined GFs. 
 
3.2 Materials and Methods 
3.2.1 Materials 
 
Polycaprolactone (PCL; Mw = 70 000 – 90 000 determined by GPC), Chloroform, 
N,N-Dimethylformamide (DMF), hexamethylenediamine (HMD), 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) and hydroxysuccinimide (NHS) were purchased to 
Sigma Aldrich and use as received. Mouse anti-Human TGF-1 monoclonal antibody was 
purchased from PrepoTech Inc. (Rochy Hill, NJ; USA), rabbit anti-Human bFGF oligoclonal 
antibody (clone 7HCLC), ABfinity recombinant, was purchased from Life Technologies 
(Carlsbad, CA; USA); and mouse-anti-Human VEGF (JH121) was purchased from Santa Cruz 
Biotechnology Inc. (Santa Cruz, USA). Regarding the secondary antibodies, both Alexa Fluor  
®488 donkey anti-rabbit IgG (H+L) and Alexa Fluor ® 594 goat anti-mouse IgG (H+L) were 
purchased from Life Technologies (Carlsbad, CA; USA). The growth factors (GFs), namely the 
recombinant human TGF-1, recombinant basic-FGF and recombinant human VEGF121 were 
all purchased from PrepoTech Inc. (Rochy Hill, NJ; USA). 
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3.2.2 Methods 
3.2.2.1 Electrospinning of nanofiber meshes 
 
A 17% (w/v) PCL solution was prepared with an organic solvent mixture of 
Chloroform and DMF in a 7:3 ratio as described elsewhere 19. The PCL solution was 
electrospun by applying a voltage of 13.6 kV, a needle tip to ground collector distance of 18 
cm and a flow rate of 1mL/h. After the complete processing of 1mL of PCL solution, the 
nanofiber mesh (NFM) was allowed to dry for 1 day. This processed NFM was cut into 
samples of 1cm x 1cm for further assays. 
 
3.2.2.2 Ultraviolet-Ozone irradiation and aminolysis 
 
For the activation of the nanofibers surface, an ultraviolet-Ozone (UV-Ozone) cleaner 
system was used (ProCleanerTM 220, Bioforce Nanoscience). Both sides of the electrospun 
NFMs were exposed during 4 minutes to UV-Ozone irradiation, as optimized previously. After 
this surface activation, amine groups (-NH2) were inserted at the surface of electrospun 
nanofibers by immersion in a 1 M HMD (Sigma Aldrich) solution during 1h at 37ºC. The 
amount of –NH2 (2.83 ± 0.11 nmol/cm2) was determined indirectly by quantifying the 
amount of free –SH groups according to Ellman’s reagent method 20. 
 
3.2.2.3 Antibodies immobilization 
3.2.2.3.1 EDC/NHS ratio and concentrations optimization 
 
EDC/NHS reagents were dissolved in 0.1 MES (2-(N-morpholino) ethanesulfonic 
acid) buffer with 0.9% (wt/wt) NaCl, following pH adjustment to 4.7, and mixed for 15 min at 
RT for antibody activation. Five different EDC/NHS ratios were tested, (i.e. 1:4, 1:2, 1:1, 2:1 
and 4:1, and the optimized ratio was further assayed at four different concentrations (10mM 
EDC + 40 mM NHS, 26 mM EDC + 104 mM NHS, 50 mM EDC + 100 mM NHS and 100 
mM EDC + 400 mM NHS). With the optimized reaction conditions, in terms of EDC/NHS 
ratio and respective concentrations, the final concentration of the linker in the antibody 
solution was determined for 1%, 5% and 10% concentrations. 
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3.2.2.3.2 Optimization of Single Antibody Immobilization and Determination of 
the Standard Curves  
Three different antibodies were immobilized (anti-TGF-1, anti-bFGF and anti-VEGF) 
at the surface of the activated and functionalized electrospun nanofiber meshes. A wide 
range of primary antibody concentrations (from 0 g/mL to 20 g/mL) was tested to find 
out the maximum immobilization capacity of the nanofibrous substrate. The electrospun 
NFMs were incubated with 200 l of each primary antibody concentration. After overnight 
incubation at 4 ºC, each mesh was washed twice with 300 l 0.1 M PBS (5 min each time) 
and a blockage of 3% BSA was performed for 30 minutes at RT. The BSA solution was 
removed and the secondary antibody (1:200 in PBS) incubated for 1h at RT. In order to 
determine the degree of immobilization, an indirect method was used to quantify the 
fluorescence of unbound secondary antibody solution (n=3 samples, read in triplicate). For 
the TGF-1 and VEGF antibodies, Alexa Fluor ® 594 was used and the reading parameters 
were the absorption at 590 nm and the emission at 617 nm. In the case of the anti-bFGF, 
the selected secondary antibody was the Alexa Fluor ® 488 and the reading parameters were 
495 nm for the adsorption and 519 nm for the emission spectrum. Negative control samples 
were also prepared, where all antibody immobilization steps were performed with the 
exception of the primary antibody incubation, which was substituted by PBS. 
 
3.2.2.3.3 Mixed immobilization of two antibodies  
 
The VEGF and bFGF antibodies were mixed in the same PBS solution at the 
concentrations optimized before, for a final volume of 200 l per mesh. The antibodies 
mixture was incubated overnight at 4ºC, and then the samples were washed twice with 0.1 M 
PBS (5 minutes each) and a 3% BSA incubation step for 30 min at RT was performed to 
block all the non-specific sites. The BSA solution was removed and the secondary antibody 
Alexa Fluor® 594 (for anti-VEGF) was incubated for 1h at RT. The exceeding secondary 
antibody solution was collect for further quantification (n=3 samples, read in triplicate), as 
previously described, and the sample washed twice. The same approach was carried out for 
the secondary antibody Alexa Fluor® 488 (for anti-bFGF). Both secondary antibodies were 
prepared in a 1:200 concentration, diluted in PBS. A negative control sample was performed, 
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without the immobilization of the primary antibodies, although all the other steps were done. 
All samples were analyzed under laser scanning confocal microscopy.  
 
3.2.2.3.4 Side-by-side immobilization of two antibodies 
 
In order to obtain a substrate with two different antibodies immobilized in a side-by-
side design, a compartmental watertight chamber was developed capable of physically divide 
a single 1cm x 2cm functionalized electrospun NFM into two distinct areas, without allowing 
the mixture of the different antibodies solutions (Figure 3.1). Two different antibody 
solutions containing (i.e. anti-VEGF and anti-bFGF) were prepared at the concentrations 
described above and dropped over each area of the functionalized electrospun NFM. All the 
antibody immobilization steps (washings, BSA blocking and secondary antibody incubation) 
were performed, as previously described for the single antibody immobilization. The 
quantification of unbound secondary antibody was also performed and the samples 
recovered to characterize the spatial distribution of the antibodies by laser scanning confocal 
microscope. 
 
Figure 3.1 Schematic representation of the compartmental watertight device that allows the 
simultaneous immobilization of two distinct antibodies in two areas of a single mesh.  
 
3.2.2.4 Laser Scanning Confocal Microscopy 
 
Laser Scanning Confocal Microscopy was conducted in order to characterize the 
spatial distribution of the antibodies at the surface of the  electrospun NFMs. The fluorescent 
labeled biological molecules were analyzed by selecting the appropriate wavelengths: 
excitation at 495 nm for Alexa Fuor ® 488 and 590 nm for Alexa Fluor ® 594, and emissions 
at 570 nm for the red channel and 540 nm for the green channel. The single and multiple 
(either mixed or side-by-side) antibodies immobilized (i.e. TGF-1, bFGF and VEGF) samples 
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were placed onto glass slides and analyzed by laser scanning confocal microcpy (FluoView  
1000, Olympus, Germany) at a 10x magnification.  
 
3.2.2.5 Recombinant and PL-derived growth factor quantification 
3.2.2.5.1 Platelets Lysates: preparation and activation 
 
Platelet Rich Plasma (PRP) was provided by the “Instituto Português do Sangue”, 
which certifies the biological product accordingly to the Portuguese law. The number of 
platelets was counted and the sample volume is adjusted to 1 million platelets per L. At the 
3B´s Research Group facilities, the collected PRP samples were subjected to a 3 repeating 
temperature-shock cycles (i.e. frozen with liquid nitrogen at −196 °C and further heated at 
37 °C) and the remaining platelets were eliminated by centrifugation. A pool of Platelet 
Lysates (PL) was stored at -20ºC until further use. At the time of each experiment, a PL 
solution was thawed and filtered with a 0.22 m filter. 
 
3.2.2.5.2 Fluorescence-Linked Immunosorbent Assay (FLISA) 
 
After completing all the antibody immobilization steps previously described, 200 l of 
the recombinant human protein solutions at different concentrations (ranging from 0 g/mL 
to the concentration of each primary antibody) were incubated for 1h at RT. The unbound 
recombinant human protein solutions were collected and stored at -20ºC until further 
quantification by ELISA. Two 0.1M PBS washing steps (5 minutes each) were performed and 
the biofunctionalized Nanofibrous substrates were incubated overnight at 4ºC with the 
corresponding primary antibody. After removal of the exceeding primary antibody solutions, 
the biofunctionalized substrates were washed again with PBS, another BSA blocking step was 
performed and the corresponding secondary antibody was incubated for 1 hour at RT. The 
fluorescence of unbound secondary solutions was also read out in a microplate reader 
(Synergy HT-BioTek). When the PL was used as the natural source of GFs, the same 
procedure was followed, although the recombinant human protein solution was substituted 
by 200 l of PL.  
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3.2.2.5.3 Enzyme-Linked Immunosorbent Assay (ELISA) 
 
For the unbound GFs quantification, human basic-FGF and VEGF development ELISA 
kits were purchased from PrepoTech (Rochy Hill, NJ; USA), whereas the human TGF-1 
ELISA kit was brought from Boster Biological Technology (Fremont, Ca; USA). For the bFGF 
and VEGF development ELISA kits, the primary antibodies were firstly incubated overnight in 
a 96-well plate (Nunc-Immuno™ MicroWell™ 96 well solid plates, Sigma Aldrich). All solutions 
were prepared according to the manufacturer protocol and, in the last step, 100 l of an 
2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid (ABTS) liquid substrate was added to 
each sample and each plate read at 405 nm and 650 nm, respectively. The TGF-1 ELISA is 
a ready-to-use kit, where the bottom wells were previously coated with the antibody. Both the 
standards and the samples were incubated and the assay conducted according to the 
protocol of the manufacturer protocol. In the last step of the procedure, 100 l of the 
3,3′,5,5′-Tetramethylbenzidine (TMB) stop solution was added to each well and the 
absorbance at 450 nm was read out (Synergy HT, Bio-TEK). 
 
3.2.2.6 Biological Assays 
3.2.2.6.1 Cell culture and seeding 
 
A human pulmonary microvascular endothelial cell line (HPMEC-ST1.6R) was used to 
validate the developed biofunctionalized nanofibrous substrate. This cell line is used to study 
in vitro angiogenic process 21. 
HPMEC-ST1.6R cells were cultured with M199 medium (Sigma Aldrich) 
supplemented with 20% FBS (Alfagene), 2 mM Glutamax (Life Technologies), Pen/Strep (100 
U/100 g/mL; Life Technologies), heparin (50 µg/mL; Sigma Aldrich), Endothelial cell growth 
supplement (ECGS - 25 µg/mL; Becton Dickinson) and incubated at 37ºC in a humidified 5% 
CO2 atmosphere. HPMEC-ST1.6R cells were used at passages 30-32. Medium was changed 
twice a week until cell reached 90% of confluence. Then, cells were harvested and seeded 
onto the activated and functionalized electrospun NFMs. 
The electrospun PCL NFMs were sterilized by ethylene oxide at Pronefro® Produtos 
Nefrológicos, S.A. (Porto, Portugal). For NFM_AB1, NFM_Ab2, NFM-VEGFRec and 
NFM+VEGFPL, VEGF antibody was immobilized overnight and, after the BSA blocking step, 
human recombinant protein (VEGF=4 µg/mL) and PL were incubated. Cell seeding was 
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performed by dropping a 50 µl cell suspension containing 50 000 cells per substrate and left 
overnight. After cell attachment, culture medium was added to each type of cells and 
conditions. Untreated electrospun PCL NFMs (NFM) and NFMs where nanofibers were 
subjected to surface activation, aminolysis and primary antibody immobilization (NFM_Ab1) 
were used as controls. After 1, 3 and 7 days of culture, samples were collected for cell 
viability assay, DNA and total protein quantification and VEGF quantification. 
 
3.2.2.6.2 Cell Viability 
 
The metabolic activity of HPMEC-ST1.6R cells seeded on untreated electrospun PCL 
NFM, NFMs with primary antibody immobilization, and biofunctionalized nanofibrous 
substrates (recombinant and PL-derived) was determined by the MTS assay (CellTiter 96 ® 
AQueous One Solution, Promega). At days 1, 3 and 7, the culture medium was removed and the 
samples were rinsed with sterile PBS. A mixture of culture medium and MTS reagent (5:1 
ratio) was added to each mesh, as well as to the negative control comprising no cells or 
samples. All conditions were performed in triplicate and left to incubate for 3h, at 37 ºC in a 
humidified 5% CO2 atmosphere. Thereafter, the absorbance of the MTS reaction medium 
from each sample was read in triplicate at 490 nm (Synergy HT, Bio-TEK). 
 
3.2.2.6.3 Cell proliferation  
 
Cell proliferation was determined by using a fluorimetric dsDNA quantification kit 
(Quant-iT™, PicoGreen®, Molecular Probes, Invitrogen, USA). The samples were collected at 
days 1, 3 and 7, washed twice with sterile PBS and transferred into eppendorf tubes 
containing 1 mL of ultrapure water. These samples were frozen at -80 °C until further 
analysis. Prior to DNA quantification, the various specimens for each samples were thawed 
and sonicated for 15 min. DNA standards were prepared at concentrations ranging from 0 to 
2 g/mL. Per each well of an opaque 96-wells plate (Falcon) were added 28.7 L of sample 
or standard (n=3), 71.3 L of PicoGreen solution and 100 L of TE buffer. The plate was 
incubated for 10 min in the dark and the fluorescence was measured in a microplate reader 
(Synergie HT, Bio-Tek; USA) by using an excitation wavelength of 480 nm and an emission 
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wavelength of 528 nm. The DNA concentration of each sample was calculated using a 
standard curve relating DNA concentration and fluorescence intensity. 
 
3.2.2.6.4 Total Protein synthesis 
 
  Samples were collected and prepared for assaying, as previously described in the Cell 
Proliferation. For the quantification of total protein synthesis, a Micro BCATM Protein Assay Kit 
(Pierce, Thermo Scientific) was used. The assay was made accordingly to the manufacturer 
instructions. Briefly, standards were prepared at various concentrations ranging from 0 
g/mL to 40 g/mL in ultra pure water. 150 L of both samples and standards were 
assayed in triplicate and 150 l of working reagent were further added to each 96-well plate. 
The plate was sealed and incubated for 2 hours at 37 ºC. The plate was left to cool down to 
RT and, thereafter, the absorbance at 562 nm was measured in a microplate reader 
(Synergy HT, Bio-Tek). 
 
3.2.2.6.5 Statistical analysis 
 
Statistical analysis was performed using Graph Pad Prism Software. Differences 
between the different conditions of the cellular assays were analyzed using non-parametric 
test (Kruskal-Wallis test) and a p<0.05 was considered significant. Data were presented as 
mean ± standard deviations. 
 
 
3.3 Results and Discussion 
  
The first task of this work was to activate and functionalize the surface of electrospun 
PCL nanofibrous meshes to allow the binding of specific growth factors from a pool of 
different proteins. In this experiment the biological fluid used in the tests was platelet lysate 
(PL). To achieve that selective binding, specific antibodies were immobilized at the 
nanofibrous substrate surface assuring that only the growth factors of interest is immobilized. 
The covalent immobilization was the preferred methodology to immobilize the antibodies at 
the surface of the chemically modified electrospun PCL nanofiber meshes (NFMs).  We 
   
57 
 
herein used carboxyl groups and amines as they tend to react leading to an efficient covalent 
immobilization 10,22. Particularly, there is a carboxyl group (-COOH) at the end of the non-
variable region of the antibodies that react with the amine groups (-NH2) that were previously 
inserted at the surface of electrospun nanofibers, leading to the covalent immobilization of an 
antibody to the polymeric substrate. In this immobilization procedure some steps were 
optimized such as the coupling agent EDC/NHS ratio and concentrations, the maximum 
immobilization capacity of the activated and functionalized electrospun nanofibers, and the 
GFs binding capacity of the nanofibrous substrate. An endothelial cell line was used as a 
living model to assess the bioactivity of bound VEGF. The successful single antibody 
immobilization strategy was then transposed to different spatial configurations, by the 
immobilization of two antibodies (i.e. anti-bFGF and anti-VEGF) in the same nanofibrous 
substrate, in a mixed or in a side-by-side fashion.  
From the most reported biomolecules present in PL (i.e. TGF-1, PDGF-, bFGF, 
EGF, IGF, and VEGF) 17,23 TGF-1, bFGF and VEGF were selected to conduct our validation 
experiments. TGF-1 has an important role in promoting the production of ECM and in 
enhancing the proliferation of both fibroblasts and osteoblasts, being therefore relevant for 
both bone and cartilage strategies 24–26. bFGF is a potent inductor of cell proliferation, 
promoting angiogenesis and differentiation, as well as collagen production. It has a significant 
function in bone, cartilage and periodontal tissues 27–29. VEGF is a promoter of angiogenesis 
and proliferation of endothelial cells, playing a pivotal role in vascularization and stem cell 
differentiation 30–32.  
 
3.3.1 Optimization of Antibodies Immobilization 
3.3.1.1 EDC/NHS ratio and concentrations 
 
  In the present study, a defined antibody was immobilized at the surface of electrospun 
nanofibers by a covalent bound mediated by a coupling agent, in this particular case the 
EDC/NHS mixture. Prior to the immobilization step, the electrospun PCL NFMs needed to be 
chemically modified by the insertion of amine groups that could react specifically with the 
carboxyl groups of the antibody 19. It is know that EDC alone is able to increase the 
immobilization efficiency of  biomolecules 9,33. However, with the addition of NHS, a two-step 
reaction occurred and the presence of NHS forms semi-stable amines, enhancing the 
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immobilization efficiency of the antibodies at the surface of a substrate 34. In order to ensure 
that the nanofibrous substrate is being used at its maximum immobilization capacity, 
different parameters concerning these two coupling reagents were tested.  
 The first parameter assessed was the ratio between the EDC/NHS coupling agents. Different 
ratios were tested (Figure 3.2 a)) and the 1:4 ratio present the highest immobilization 
efficiency and lower variability being therefore selected for further experiments. Looking at 
the different ratios it seems that higher concentrations of NHS lead to a higher efficiency of 
immobilization. With the selected ratio, the next step was to optimize the concentration of 
each individual coupling agent (Figure 3.2 b)). From the four concentrations tested, the one 
that yields less variability and higher efficiency was the 50 mM EDC + 200 mM NHS and, 
therefore, the one selected for further experiments. The final step of this optimization process 
relies on testing the concentration of the EDC/NHS mixture in the final antibody solution. The 
EDC/NHS concentration that got higher immobilization efficiency was the 1% (v/v), since the 
amount of immobilized antibody decreases with the increase of EDC/NHS concentration 
(Figure 3.2 c)). Based on these results, all further experiments concerning antibodies 
immobilization will use the following optimized conditions: 1:4 ratio, 50mM EDC + 200 mM 
NHS concentrations and 1% (v/v) EDC/NHS concentration in the primary antibody solution. 
 
Figure 3.2 EDC/NHS ratio and concentrations optimization. (a) optimization of the coupling agents 
EDC/NHS ratio; (b) optimization of the individual EDC and NHS concentrations, maintaining the 
previously optimized ratio 1:4; (c) optimization of the final concentration of the EDC/NHS mixture 
(50 mM EDC + 200 mM NHS, optimized before)  in the antibody solution. 
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3.3.2 Single antibody immobilization at the Nanofibrous surface 
3.3.2.1 Antibodies immobilization efficiency 
 
  The antibodies against the growth factors TGF-1, bFGF and VEGF were immobilized at 
the surface of activated and functionalized electrospun nanofibers, in a wide range of 
concentrations (0 – 20 g/mL), to determine the maximum immobilization capacity of the 
nanofibrous substrate for each antibody. To achieve that purpose, an indirect quantification 
method was used, based on the measurement of unbound secondary antibody fluorescence, 
after its incubation with the immobilized primary antibody. As observed in Figure 3.3, the 
higher amount of immobilized primary antibody corresponds to the lower fluorescence signal 
of the free secondary antibody. When the fluorescence signal reaches a plateau, the 
nanofibrous substrate presents the maximum concentration of immobilized primary antibody, 
reaching the saturation of the system. With the anti-TGF-1, the maximum concentration of 
immobilized primary antibody is 12 g/mL; in the case of anti-bFGF, the maximum capacity 
of the nanofibrous substrate is 8 g/mL; whereas with the anti-VEGF its concentration 
reaches a value of 4 g/mL. As clearly noticed, the different antibodies have different 
densities over the same activated and functionalized nanofibrous substrate. This observation 
may be related with the different sizes of the primary antibodies used. According to 
manufacturer’s data the size of anti-VEGF is approximately 22 kDa and anti-bFGF is 17 kDA. 
In the case of the anti-TGF-1 no information is given by the company although according to 
other manufacturers, the molecular weight of anti-TGF-1 should be around 12-14 kDA. The 
immobilization data correlates with the antibodies size, since the more surface area is 
occupied by the antibody, the lower is its concentration at the nanofibers surface. Therefore, 
further experiments were performed with the concentrations of the primary antibodies that 
lead to the maximum immobilization capacity of the nanofibrous substrate. Antibodies were 
immobilized in different subtracts as referred before in a similar fashion as the common  
ELISA methods, that also involve the immobilization of specific antibodies at the bottom of 
the well to quantify the amount of  specific antigen existing in a sample. From the datasheet 
of the ELISAs, referred in the materials and methods section, it is possible to conclude that 
the values for anti-bFGF and anti-VEGF immobilization is 1 μg/mL and 0.5 μg/mL, 
respectively. The ELISA tests are conducted in 96 well-plates having approximately 0.32 cm2 
of surface area per well. In the case of the developed biofunctionalized nanofibrous substrate 
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the apparent surface area is about three times higher (1cm2) and despite having the same 
ratio between them the immobilization capacity is 8 times (8 g/mL for anti-bFGF and 4 
g/mL for anti-VEGF)higher than in the standard ELISAs.  
 
Figure 3.3 Maximum immobilization capacity of a single antibody at the surface of activated and 
functionalized electrospun nanofiber: a) immobilization of anti-TGF-1, b) immobilization of anti- bFGF 
and c) immobilization of anti-VEGF.   
 
3.3.2.3 Primary antibodies standard curve 
 
  After determining the maximum antibody concentration immobilized at the surface of the 
activated and functionalized electrospun nanofibers, a standard curve was determined for 
each antibody. With the remaining solution of each secondary antibody, it was possible to 
determine the amount of unbound secondary antibody, leading indirectly to the concentration 
of primary antibody that was immobilized. A linear regression standard curve fitting those 
data points allowed obtaining a R2 above 0.98 for every antibody (Figure 3.4). These 
standard curves were further used for the quantification of the immobilized antibodies in next 
assays. 
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Figure 3.4 Standard curves for single antibody immobilization at the surface of activated and 
functionalized electrospun nanofibers.  a) TGF-1 antibody standard curve varying between 0 g/mL 
and the maximum concentration that can be immobilized (i.e. 12 g/ml). b) bFGF antibody standard 
curve ranges from 0 g/mL to 8 g/mL; and c) VEGF antibody standard curve varies between 0 
g/mL and 4 g/mL. 
 
3.3.2.2 Spatial distribution of antibodies at the surface of electrospun 
nanofibers 
 
   The spatial distribution of the TGF-1, bFGF and VEGF antibodies at the surface of 
activated and functionalized electrospun nanofibers is shown in Figure 3.5. All the 
immobilized antibodies seem to be uniformly distributed through the nanofibers surface, 
resembling the random mesh-like arrangement of the electrospun NFM structure. The TGF-
1 antibody seems to have a more intense and densely distributed fluorescence than the 
other immobilized antibodies, probably due to its higher concentration (12 g/mL). To 
ensure that the secondary antibody only binds to the immobilized primary antibody, we 
defined a control experiment in which all the steps were performed except the incubation 
with the primary antibody. These conditions were analyzed for fluorescence (Figure 3.5 d), 
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e) and f)) and no fluorescence was detected. Since no fluorescent signal was observed , it 
means that Alexa Fluor ®594 and Alexa Fluor ® 488 secondary antibodies were not 
immobilized at the surface of activated and functionalized electrospun nanofibers, confirming 
the specific binding between these two secondary antibodies and the corresponding 
immobilized primary antibodies. 
 
Figure 3.5 Spatial distribution of immobilized primary antibodies at the surface of activated and 
functionalized electrospun nanofibers. Primary antibodies were immobilized at the previous optimized 
concentrations: a) 12 μg/mL of anti-TGF-1, b) 8 μg/mL of anti-bFGF and c) 4 μg/mL of anti-VEGF. 
In the case of the TGF-1 and VEGF antibodies, the secondary antibody Alexa Fluor ® 594 was used, 
whereas the secondary antibody Alexa Fluor® 488 was used for the bFGF antibody.  The negative 
controls d), e) and f) were subjected to all the steps except the incubation with the primary antibodies. 
 
3.3.3 Growth Factors binding capacity to the biofunctionalized nanofibrous 
substrate 
3.3.3.1 Quantification of bound recombinant proteins 
 
  After confirming the specific immobilization of the TGF-1, bFGF and VEGF antibodies 
and determining the corresponding standard curves, it was assessed the binding capacity of 
the biofunctionalized nanofibrous substrates. Namely it was characterized the total amount of 
each growth factor that a functionalized mesh can bind. For that, two different growth factor 
(GF) sources were tested: (i) recombinant proteins to evaluate the maximum binding capacity 
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of the biofunctionalized nanofibrous substrate, and (ii) PL-derived GFs to assess the selective 
binding capacity of the biofunctionalized nanofibrous substrate. In fact, when using 
recombinant protein, we know that the only protein competing to the primary antibody is the 
one being tested. In PLs we have a complex mixture of proteins competing for the antibodies, 
thus demonstrating the specificity of the bound proteins. 
Following the immobilization of each antibody at the surface of the activated and 
functionalized electrospun nanofibers, the corresponding recombinant protein was added at 
different concentrations, varying from 0 g/mL to values higher than the concentration of the 
previously immobilized primary antibody. However, for all the three antibodies in study, the 
biofunctionalized nanofibrous substrate starts to reach its maximum GF binding capacity near 
to the higher concentration of the primary antibody as showed in Figure 3.6 (i.e. 12 g/mL 
for TGF-1, 8 g/mL for bFGF and 4 g/mL for VEGF). The results were also confirmed and 
quantified with commercial available ELISA and the maximum loading capacity corresponded 
to the above mentioned values, reaching around 100% of loading efficiency for all the three 
GFs. As observed in Figure 3.6, an increase in the amount of recombinant protein leads to 
a decrease in the fluorescence signal, meaning that less secondary antibodies are unbound. 
It is important to notice that each GF-bound to the biofunctionalized nanofibrous substrate 
has its own slope or rate.  The higher slope is observed for TGF-1 (40,833), followed by the 
one for bFGF (27,259) and the lower one for VEGF (21,771). The possible explanation for 
this observation relies on the fact that higher concentrations of primary antibodies are 
occupied faster by the corresponding recombinant protein, leading to a rapid decrease on the 
fluorescence signal of the unbound secondary antibody. TGF-1 has been previously 
reported to be immobilized in different substrates like gelatin 35 and magnetic beads 36 
whereas bFGF has been immobilized into different platforms like, PEG hydrogel 37, PLGA films 
38 and PLLA+collagen scaffolds 39. VEGF has been covalently immobilized into different 
substrates such as collagen scaffolds 40,41, PLGA 42 and hydrogels 43. From all this literature 
data, it was possible to conclude that our nanofibrous substrate enables immobilizing a 
higher concentration of GFs at the order of g/mL, whereas most of the other system 
reported values that are at the magnitude of ng/mL, reflecting the positive effect of the 
increased surface area of the electrospun nanofibers over the bound GFs. 
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Figure 3.6 Capability of the biofunctionalized nanofibrous substrate to bind different concentrations 
of the recombinant protein: a) TGF-1, b) bFGF and c) VEGF. 
 
3.3.3.2 Quantification of bound PL-derived growth factors  
We quantified the amount of each GF of interest in the PL by an ELISA kit. Table 
3.1 shows the range of concentrations obtained from two different human samples. 
Comparing to other values reported in the literature, TGF-1(169.9±84.5 ng/mL) is about 15 
times higher than the ones obtained with our own samples whereas the values of VEGF are 
comprised in the reported values (0.076 to 0.854 µg/mL)17. Despite being described as one 
of the most abundant GFs of PRP samples, we found no data reporting the concentration of 
bFGF in the literature. The differences of the quantified GFs and its variability are related with 
the differences between donors leading to different concentrations of the GFs of interest. 
Table 3.1 Quantification of the growth factors of interest derived from two human PL samples 
Growth 
Factors 
Concentration in PL samples % Binding 
Donor 1 Donor 2 Donor 1 Donor 2 
TGF-1 4.2 ng/mL 11.05 ng/mL 83.92 ± 2.68 86.85 ± 3.26 
bFGF 8.6 ng/mL 102.5 ng/mL 54.78 ± 4.75 63.97 ± 3.48 
VEGF 0.0949 ng/mL 0.4263 ng/mL 49.52 ± 3.05 58.85 ±4.02 
After determining the recombinant human GF binding capacity of the activated and 
functionalized nanofibrous substrate, it was tested for the selective binding of GFs derived 
from the PL samples. ELISAs were performed to determine the amount of bound autologous 
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GFs for two different donors. For PL-derived TGF-1, the binding efficiency (around between 
84% - 87%) was not as high as in the case of the recombinant protein. Considering the bFGF, 
only around 55% - 64% of PL-derived protein was bound to the nanofibrous substrate 
immobilized primary antibody. The same trend was observed for the VEGF, where about 50% 
-58% of PL-derived VEFG was bound by the corresponding immobilized antibody. Despite the 
concentrations of the GFS in the different samples the bounding of the GFs stayed in the 
same range for the two donor samples, showing the consistency of the method. 
 Despite the order of magnitude differences in the concentration of GFs present in the PL 
(ranging from pg/mL for VEGF to ng/mL for TGF-1 and bFGF), those concentrations are 
much lower than the ones determined for the maximum binding capacity of the 
biofunctionalized nanofibrous substrate where recombinant proteins were used at g/mL. 
The inability of the biofunctionalized nanofibrous substrate to immobilize 100% of the GFs 
amount present in the PL can be related with the fact that this biological fluid is highly rich in 
different GFs and proteins that can compete to the binding sites of each immobilized 
antibody. Another technical aspect that can justify the binding of GFs derived from the PL in 
the range of 50-87% is the detection limits of the used ELISAs, which do not enable detecting 
the GFs at very low concentrations (16 pg/mL for VEGF ELISA Kits, 63 pg/mL for bFGF and 
15.6 pg/mL for TGF-1). 
 
3.3.4 VEGF biological activity 
 
To confirm that the covalent immobilization method do not compromise the 
bioavailability of the antigen binding site of the antibodies and the behavior of the bound 
growth factors we assessed  the bioactivity of bound VEGF. VEGF has been described to 
induce vascularization and angiogenesis so human pulmonary microvascular endothelial cells 
(HPMEC-ST1.6R cell line) were seeded onto the biofunctionalized electrospun nanofibrous 
substrates. VEGF condition was selected since VEGF is less concentrated factor in Platelet 
Lysate so we assessed the bioactivity for the worst (less concentrated) scenario. Different 
biological assays were conducted to assess the endothelial cells viability and proliferation, the 
total protein synthesis, as well as the quantification of intracellular synthesis of VEGF (Figure 
3.7). The endothelial cells were cultured at the surface of 5 different substrate conditions : i) 
untreated electrospun PCL NFM (NFM), ii)  NFM with primary antibody (NFM_Ab1), iii) 
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electrospun NFM with bound recombinant VEGF (NFM+VEGFRec), iv) electrospun NFM with PL-
derived VEGF (NFM+VEGFPL) and v) NFM with primary anti-VEGF (NFM_Ab2). In conditions i) 
and ii)  the medium was supplemented with Endothelial Cell Growth Supplement (ECGS), a 
mixture of growth factors aimed to stimulate the growth of human and animal vascular 
endothelial cells 44,45. In conditions iii), iv) and v) the endothelial cells were cultured in basal 
medium since we wanted to evaluate the actions of the immobilized form of VEGF so the 
medium was not supplemented by other GFs.  
Our data confirms the biological activity of the bound VEGF, since in all the assays 
performed (cell proliferation, cell viability, total protein synthesis and intracellular VEGF), we 
always report significant differences between the NFM+VEGFRec and NFM+VEGFPL when 
compared to NFM_Ab2 (this condition only differs from the previous one by not having an 
immobilized protein). This observation undoubtedly demonstrates that bound VEGF 
(recombinant or PL-derived) indeed make a difference in the biofunctionalized nanofibrous 
substrate. Furthermore, no significant differences were observed at first day, regarding the 
cell DNA content (Figure 3.7 a)), confirming the similar number of cells seeded over the 
different substrate. Since there are no significant differences between NFM+VEGFPL and 
NFM+VEGFRec even at a much higher concentration of recombinant VEGF (4 g/mL) it is 
possible to conclude that the amount of protein derived from PL samples (0.251 g/mL) is 
enough to induce cells proliferation. Although an excess of immobilized recombinant protein 
did not have adverse effects on the endothelial cells. Our controls do not present significant 
differences among them showing that the chemical treatment do not affect cells behavior. 
Another important aspect of those cellular experiments is the observation of significant 
differences between the bound VEGF and the conditions where the GFs are given in its 
soluble form (NFM and NFM_Ab1) demonstrating its bioactivity along time. This same trend 
has already been reported showing some evidences that the immobilized form can be 
beneficial for endothelial cells metabolic activity and protein synthesis 40. This is probable due 
to the fact that immobilized VEGF can provide a more controlled and sustained influence over 
the cells, comparing with the transient effect of soluble VEGF. GFs immobilization in 
substrates also promotes a local regulation and control over cellular activity, as expressed by 
the intracellular VEGF over expression. Furthermore, immobilized growth factors can provide 
extended signaling since the ligant will not be internalized as a ligant/receptor complex. 
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Covalent attachment of angiogenic growth factors to biomaterial scaffolds is a advantageous 
strategy for the development of polymeric matrix with enhanced angiogenic capabilities.46 
 
 
Figure 3.7 Biochemical performance of the endothelial cell line cultured on unmodified electrospun 
PCL NFM, NFM with immobilized VEGF antibody (NFM_Ab1), both in supplemented medium (ECGS); 
NFM with immobilized VEGF antibody (NFM_Ab2), NFM with bound recombinant VEGF (NFM+VEGFRec) 
PL-derived VEGF (NFM+VEGFPL) with non supplemented media a) Cell Proliferation, b) cell viability, c) 
total protein synthesis and d) intracellular VEGF synthesis. Statistical analysis was performed for the 
five different conditions comparing each time point (Day 1, Day 3 and day 7). Data was considered 
statistical different for p values < 0.05. (*) denote significant differences when compared to NFM 
condition, (+) when compared to NFM_Ab1 supplemented media, (x) when compared to NFM_Ab2, (#) 
when compared to NFM_VEGF and (&) when compared to NFM_PL. 
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3.3.5 Immobilization of multiple antibodies in different spatial configurations 
 
Our methodology herein reported aims at immobilizing more than one antibody at 
the surface of a single activated and functionalized NFM. Two different immobilization 
designs will be presented: one with the mixed distribution of defined antibodies (i.e. anti-
VEGF and anti-bFGF) and another with side-by side localization of those distinct antibodies, in 
different areas of the same nanofibrous substrate. With the immobilization of multiple 
antibodies at the surface of the same nanofibrous substrate it is expected to develop a highly 
efficient system for designing advances strategies for diverse cell biology, tissue engineering 
and regenerative medicine. 
 
 
3.3.5.1 Mixed immobilization of two different GFs 
 
The purpose of the mixed immobilization is to have, at the surface of the same 
nanofibrous substrate, two different but complementary antibodies, specifically the anti-bFGF 
and anti-VEGF. To implement this strategy, the antibodies concentrations optimized before 
(i.e. 8 g/mL for bFGF and 4 g/mL for TGF-1) were used and incubated simultaneously. 
The Figure 3.8 a) express how much of the initial antibodies concentrations have 
been immobilized, being these results obtained by applying the determined standard curves 
for the single antibody immobilization strategy (Figure 3.4). In the case of anti-bFGF, 
around 63% of the initial antibody concentration was immobilized, whereas around 72% of 
the initial concentration was immobilized in the case of VEGF antibody. These immobilization 
efficiencies were above the expected outcomes, since the two antibodies, although at 
different concentrations, are competing for the same amount of NH2 available at the surface 
of an activated and functionalized nanofibrous substrate. The antibodies can be immobilized 
until the system reaches its maximum capacity, not having more chemical groups available 
for the antibodies immobilization. Therefore, in the mixed distribution of two antibodies is 
reasonable that the immobilization efficiency could not be as high as for the single 
immobilization strategy. Human PL samples were also incubated with the mixed 
immobilization nanofibrous substrate to evaluate if this system was able to bind selectively 
and simultaneously the two growth factors of interest. As observed in Figure 3.8 b), the 
binding efficiency was about 64% for bFGF and 65% for VEGF.  
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Figure 3.8 (a) Quantification of mixed immobilized bFGF and VEGF antibodies. (b) relative 
quantification of bound GFs (i.e. VEGF and bFGF) derived from PL. 
To evaluate the spatial distribution and confirm that both antibodies were indeed 
immobilized at the same nanofibrous substrate in a mixed design, the corresponding 
secondary antibodies were used and their fluorescence observed at the laser scanning 
confocal microscope.  
Figures 3.9 a) and b) represent the Alexa Fluor ®488 and the Alexa Fluor ®594 
fluorescent antibodies bound to the anti-bFGF and anti-VEGF at the surface of activated and 
functionalized nanofibrous substrate. It is possible to observe that the antibodies are 
uniformly distributed over the functionalized nanofibrous substrate. However, it is also 
possible to notice that the green fluorescence is slightly more intense than the one 
concerning anti-VEGF immobilization. This may be related with the higher concentration of 
the immobilized anti-bFGF, which can lead to higher intensity of Alexa Fluor ® 488 antibody 
fluorescence. Figure 3.9 c) represent the merge of the two different 
channels/fluorescences (green and red), corresponding to the VEGF and bFGF immobilized 
antibodies distribution. The merging of the two pictures yield a significant amount of yellow 
spots which demonstrate the co-localization of both antibodies in a mixed fashion, over the 
same nanofibrous substrate. Finally Figure 3.9 d) presents the negative control of the 
experience, where the incubation step with the primary antibodies solution was not 
conducted to make sure that the secondary antibodies are only bind to the corresponding 
primary antibodies. 
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Figure 3.9 Spatial distribution of the mixed immobilized primary antibodies at the surface of a single 
activated and functionalized Nanofibrous substrates. The bFGF and VEGF antibodies were 
simultaneously immobilized in the same mesh, at the previously optimized concentrations. a) Alexa 
Fluor ® 448 was used as the secondary antibody for the anti-bFGF); b) the Alexa Fluor ® 594 was used 
for the anti-VEGF; c) the spatial distribution of the two primary antibodies (merge view); and d) 
activated and functionalized Nanofibrous substrates without primary antibodies immobilization.  
 
3.3.5.2  Side-by-side immobilization of two distinct antibodies 
 
With the side-by-side immobilization of two antibodies we intend to demonstrate the 
possibility to have two distinct GFs selectively immobilized from biological fluids, bound side 
by side, having in mind their functional role over two distinct cell types spatially juxtaposed in 
physiological environments.  In order to achieve this purpose, a compartmental watertight 
device was designed to enable creating two distinct areas in the same nanofibrous substrate. 
Each area of the activated and functionalized nanofibrous substrate was incubated with the 
defined primary antibody and, further with the corresponding secondary antibody, leading to 
the side-by-side configuration and distribution presented in Figure 3.10. The reddish 
fluorescent area of the nanofibrous substrate corresponds to the anti-VEGF immobilization, 
a) b)
c) d)
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whereas the green area reports to the bFGF antibody immobilization. The black area 
corresponds to the bar that separates the same nanofibrous substrate into the two areas. It 
is possible to detect local green spots or red dots which can be due to some diffusion of the 
antibodies solution trough the activated and functionalized nanofibrous substrate. 
With this system it will be possible to seed and culture two different cell types over 
the two areas of the biofunctionalized nanofibrous substrate, where defined antibodies and 
the corresponding GFs are previously immobilized. With this strategy it will be possible to 
obtain tailored and advanced co-culture systems, allowing to study cell-cell interactions in 
vitro in the present of specific GFs. 
 
Figure 3.10 Laser scanning confocal microcopy image demonstrating the side-by-side antibodies 
immobilization over the same activated and functionalized Nanofibrous substrate. 
3.4 Conclusions  
 
  The covalent immobilization method was successfully implemented in nanofibrous 
substrates, presenting different efficiencies depending on the antibody of interest. After the 
antibodies immobilization in different designs, the biofunctionalized nanofibrous substrates 
enabled the binding of the corresponding growth factors, as well as to select a specific GF 
from a complex biological fluid (i.e. PLs) comprising a pool of different GFs and proteins. The 
bioactivity of the bound growth factors was confirmed by cell culture assays, and the 
beneficial outcomes of the nanofibrous substrate bound GFs were confirmed by biochemical 
data. The biological data suggests that this substrate offers unique possibilities to study basic 
cell biology as well as tissue engineering and regenerative medicine fields, since it is possible 
to specifically bind different GFs of interest at the surface of the nanofibrous substrate. 
Ultimately, using both biological fluids and cells from an autologous source, it will be possible 
to implement very effective and personalized therapies tailored for specific clinical conditions. 
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Chapter 4 
General Conclusions and Future Work 
 
4.1 General Conclusions 
 
The activation and functionalization of electrospun polycaprolactone (PCL) nanofibers 
surface allowed the insertion of defined chemical cues, -NH2 groups, that can react with the 
COOH from the antibodies forming a stable covalent immobilization. From the optimization 
study it was possible to optimize the ratio of EDC/NHS and its concentrations, to obtain the 
maximum immobilization capacity of the nanofibrous substrate. 
Different antibodies demonstrated different immobilization densities over the same 
polymeric substrate. We proposed that the different densities are dependent on the size the 
antibodies, since higher concentrations of immobilization are obtained with antibodies of lower 
molecular weight. A standard curve, correlating the different concentrations of each antibody 
was also obtained demonstrating the linearity of the immobilization method. Confocal 
microscopy analysis of single antibodies immobilization confirmed that the secondary 
antibody could specifically link to the immobilized primary antibody, demonstrating the 
specificity and the efficiency of this methodology. Furthermore, the antibodies immobilization 
method was effective, since the correspondent growth factors were successfully bound and 
further quantified. We determined the maximum binding capacity of the recombinant proteins 
showing that those values stabilize for the maximum concentration of the immobilized 
antibodies. The amount of PL-derived GFs was determined and, at least, approximately 50% of 
each GF was selectively bound to its corresponding antibody. The bioactivity of the bound-
VEGF (Recombinant and PL-derived) was assessed by seeding and culturing a specific cell line 
(HPMEC-ST1. R6) over the activated and functionalized nanofibrous substrate. Biological data 
showed significant differences when bound VEGF (either recombinant or from PLs) was 
compared to the nanofibrous substrate without VEGF (only the primary antibody immobilized). 
This observation showed that the VEGF is indeed specifically bound, bioactive and provides 
beneficial cellular outcomes. Furthermore, the immobilized form of VEGF even showed 
significant differences when compared to the soluble ECGS supplemented in the culture 
medium demonstrating that the presence of the GFs at the surface and in the vicinity of the 
 78 
 
seeded cells maximizes its bioactivity. With the immobilization of more than one antibody it 
was possible to assess the selective bound of two different GFs from PLs in a homogenous 
and mixed distributed form. With the side-by-side immobilization of two antibodies (in this 
case bFGF and VEGF) the developed watertight chamber system enabled separating the 
functionalization of a single NFM immobilized with two different antibodies. This strategy 
allows validating strategies to further design advanced therapies, which combine in a single 
device various biomolecules enhancing surface functionalization.  
 
4.2 Future Work 
 
This strategy will allow for the immobilization of single or multiple antibodies, and 
corresponding GFs binding depending on the target applications. It is  proposed, as future 
work,  the evaluation of the mixed immobilization of two GFs with complementary roles by 
assessing their bioactivity and functionality by culturing human mesenchymal stem cells 
(MSCs), and driving its differentiation into a defined lineage (e.g. osteogenic or chondrogenic). 
With the side-by-side immobilization strategy it is possible to have two distinct GFs in different 
areas of the same substrate enabling elucidates its functional role over two distinct cell types. 
Therefore, the two types of cells (e.g. endothelial/osteoblasts or osteoblasts /chondrocytes) 
could be seeded over the two distinct areas of the nanofibrous substrate, where a certain 
antibody and the corresponding GF were previously immobilized. With this strategy it would be 
possible to obtain tailored co-culture systems, allowing to study GF-mediated cell-cell 
interactions. To assess the in vivo efficiency of the immobilized antibody or bound GF on this 
nanofibrous substrate, these biofunctionalized substrates will be also studied and its 
functionality in vivo validated in relevant animal models. 
This versatile immobilization strategy can be to transpose to different polymeric 
substrates currently in use in the clinic, namely bioresorbable devices (i.e. meshes, screws).  
In particular wound dressing meshes (for diabetic ulcers) or membranes for guided tissue 
regeneration in the context of dentistry are in the frontline of the translational of this strategy 
into the clinic. 
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